theranos

Confidential Overview

goodbye, big bad needle.

Theranos, Inc.

Headquartered in Palo Alto, California, Theranos is a Silicon Valley-based company founded in 2003.

Theranos' proprietary, patented technology runs comprehensive blood tests from a finger-stick and tests from micro-samples of other matrices, and generates significantly higher integrity data than currently possible.

Theranos is the world's first and only CLIA-certified laboratory running its tests on micro-samples. Clinical Lab Improvement Amendments

Current and past clients include 10 of the top 15 major pharmaceutical companies, midsized bio-pharmas, prominent research institutions, healthcare payors, and U.S. and foreign government health and military organizations.

Our mission is to make actionable health information accessible to everyone at the time it matters.

Our Board

Elizabeth Holmes: Theranos Chairman, CEO, and Founder

George P. Shultz: Former U.S. Secretary of State, Secretary of Treasury, Secretary of Labor, and President of Bechtel

Gary Roughead: Former United States Admiral and Chief of Naval Operations

William J. Perry: Michael and Barbara Berberian Professor at Stanford University; former U.S. Secretary of Defense

Sam Nunn: Co-chairman and CEO of NTI; former United States Senator and Chairman of the Senate Armed Services Committee and the Permanent Subcommittee on Investigations

Richard Kovacevich: Former CEO of Wells Fargo & Company

James N. Mattis: Retired U.S. Marine Corps general and commander of the United States Central Command

Henry A. Kissinger: Former United States Secretary of State, Assistant to the President of the United States for National Security Affairs, and recipient of the Nobel Peace Prize

William H. Frist: Chairman of the Executive Council of Cressey and Company, former U.S. Senate Majority Leader

William H. Foege: Former Director of CDC, epidemiologist and health innovator behind the successful campaign to eradicate smallpox

Riley P. Bechtel: Chairman of the Board and a Director of Bechtel Group, Inc.

Sunny Balwani: Theranos President and COO

Theranos is certified as a High Complexity CLIA Laboratory

Waived	Simple, accurate tests without routine oversight
Moderate	Most tests fall in this category; automated testing where the lab must meet standards and surveyed biennially
PPM	Provider performed microscopy; the lab must meet quality standards; no routine oversight
High Complexity	Requires the highest level of training, technique and result interpretation; most stringent standards; labs are surveyed routinely and randomly

CENTERS FOR MEDICARE & MEDICAID SERVICES

CLINICAL LABORATORY IMPROVEMENT AMENDMENTS

CERTIFICATE OF COMPLIANCE

LABORATORY NAME AND ADDRESS

THERANOS INC
1601 S CALIFORNIA AVE
PALO ALTO, CA 94304-1111

CLIA ID NUMBER

05D2025714

EFFECTIVE DATE

01/09/2014

LABORATORY DIRECTOR

ADAM ROSENDORFF MD DIRECT

EXPIRATION DATE

01/08/2016

Pursuant to Section 353 of the Public Health Services Act (42 U.S.C. 263a) as revised by the Clinical Laboratory Improvement Amendments (CLIA), the above named laboratory located at the address shown hereon (and other approved locations) may accept human specimens for the purposes of performing laboratory examinations or procedures.

This certificate shall be valid until the expiration date above, but is subject to revocation, suspension, limitation, or other sanctions for violation of the Act or the regulations promulgated thereunder.

CMS

Judith A. Yost, Director
Division of Laboratory Services
Survey and Certification Group
Center for Clinical Standards and Quality

Theranos Proficiency Testing and Audits

Since 2011 Theranos' CLIA lab has been subjected to regular proficiency testing (testing of blinded samples) by multiple nationally recognized agencies. The lab is also audited and inspected every two years by CLIA and also by the New York Department of Health. Theranos successfully completed these most recent inspections in June '14 and December '13, respectively. Additional representative surveys include:

Agency Survey	Date	Score
API Hematology	11/23/2011	100%
API Chemistry / Immunology / Immunochemistry	6/1/2012	100%
NY Clinical Chemistry	9/10/2012	100%
API Hematology / Coagulation / Body Fluid	11/28/2012	100%
CAP Infectious Disease, Respiratory -A	4/9/2013	100%
API Microbiology	7/9/2013	100%
NY Oncology	1/28/2014	100%
CAP Chlamydia / GC	6/23/2014	100%
CAP Hepatitis Viral Load-B	7/1/2014	100%

Validation of Theranos Tests

Theranos has been comprehensively validated over the course of the last seven years by ten of the fifteen largest pharmaceutical companies, with hundreds of thousands of assays processed.

After running clinical trials with Theranos instead of the central laboratory, GlaxoSmithKline's Lab Director concluded that **"Theranos' lab infrastructure eliminates the need for a lab."**

Theranos calibrates and validates its systems to FDA, CDC, ICH and World Health Organization guidelines and standards where accessible.

Excerpts from Johns Hopkins due diligence and technology validation:

- "The technology is novel and sound. It can accurately run a wide range of routine and special assays."
- **"No major weaknesses were identified."** JOHNS HOPKINS MEDICINE

For the first time,
tests can be done with just a tiny sample,
and at a fraction of the cost


the only thing you should feel is better.
the blood test, reinvented.
theranos

Overview of Current Laboratory Market

- Decades old business processes - and technology investments around those business processes - with very little motivation to innovate, has created a duopoly of businesses burdened with infrastructure costs and little/no R&D.

Quest
Labcorp

- Manual handling of samples at every step of the process yields significant quality and usability issues with current lab results.
- Select contracts between labs and insurance companies have set precedent for higher costs for "pull through" patients.
- Healthcare reform, increasing healthcare costs, and the changing market dynamics make this industry ripe for innovation.

Access to Actionable Health Information at the Time it Matters

Access:

- Unprecedented cost
- Micro-samples
- Geo-access
- Convenience: extended hours of operation
- Speed of results

Actionable Information:

- High Complexity CLIA certified laboratory
- Automation and standardization
- Reflex across test methodologies
- Longitudinal data
- Screenings

Cost Savings

The full range of tests. A fraction of the costs.

Theranos is committed to making lab testing more accessible to everyone. That means pricing our tests dramatically lower than currently available options.

We can bill all major insurance carriers as well as Medicare and Medicaid.

Uninsured patients are offered the same discounted prices.

Cost Savings (continued)

- Many of Theranos' initial price points are 70% below Medicare reimbursement amounts for all currently run tests/CPT codes.
- Theranos Systems in physician offices stamp out leakage problems/out-of-network testing at the root of the problem.
- Real-time testing and reflex testing during office visits enable better physician decision making and reduced visits by eliminating test result delays.
- Real-time data in ER & hospitals reduces hospital bed stays and costs.
- The unprecedented lack of variation from system to system yields higher integrity data and longitudinal trending, enabling earlier insight into the onset/progression of disease and reducing unnecessary secondary procedures from results which currently show up as false positive results.
- Earlier insight into disease progression and earlier intervention will reduce ER/hospital visits.

Exemplary Price comparison

Test	Standard Lab Costs*	Medicare Price	Theranos Price
Comprehensive Respiratory Panel	$1,222.30	$1,000.00	**$49.95**

Theranos' prices translate into meaningful savings for all payer channels and cash paying members.

Theranos price = 95% discount to Medicare

Exemplary Price comparison

Test	Standard Lab Costs*	Medicare Price	Theranos Price
Chlamydia/ Gonorrhea	$200.00	$95.74	**$29.95**

Theranos' prices translate into meaningful savings for all payer channels and cash paying members.

Theranos price = 70% discount to Medicare

Exemplary Price comparison

Test	Standard Lab Costs*	Medicare Price	Theranos Price
Hepatitis C Genotyping	$674.00	$353.88	**$117.96**

Theranos' prices translate into meaningful savings for all payer channels and cash paying members.

Theranos price = 67% discount to Medicare

Cost Savings: National Medicaid

Est. Direct Out-of-Pocket Lab Cost Savings for National Medicaid

10-year aggregate savings of $67 billion

Est. Cost Savings from Reduced Visits for National Medicaid



10-year aggregate savings of $157 billion

Cost Savings: National Medicare

Est. Direct Out-of-Pocket Lab Cost Savings for National Medicare

10-year aggregate savings of $102 billion

Est. Cost Savings from Reduced Visits for National Medicare

10-year aggregate savings of $218 billion

Source: CMS.gov, KFF.org and Theranos estimates.
Spend per visit estimated based on national averages.

Cost Savings: Arizona Medicaid

Est. Direct out-of-pocket Lab Cost Savings for Arizona Medicaid

10-year aggregate savings of $1.4 billion

Est. Cost Savings from Reduced Visits for Arizona Medicaid



10-year aggregate savings of $3.6 billion

Source: CMS.gov, KFF.org and Theranos estimates.
Spend per visit estimated based on national averages.

Cost Savings: Arizona Medicaid (cont'd)

Est. Combined Impact on Lab Costs & Reduced Visits for Arizona Medicaid



10-year aggregate savings of $4.9 billion

Source: CMS.gov, KFF.org and Theranos estimates.
Spend per visit estimated based on national averages.

Cost Savings: Arizona Medicare

Est. Direct out-of-pocket Lab Cost Savings for Arizona Medicare

10-year aggregate savings of $2.0 billion

Source: CMS.gov, KFF.org and Theranos estimates

Cost Savings: California Medi-Cal

Est. Direct out-of-pocket Lab Cost Savings for California Medi-Cal



10-year aggregate savings of $7.7 billion

Est. Cost Savings from Reduced Visits for California Medi-Cal



10-year aggregate savings of $21.3 billion

Source: CMS.gov, KFF.org and Theranos estimates.
Spend per visit estimated based on national averages.

Cost Savings: California Medi-Cal (cont'd)

Est. Combined Impact on Lab Costs & Reduced Visits for California Medi-Cal



10-year aggregate savings of $28.9 billion

Source: CMS.gov, KFF.org and Theranos estimates.
Spend per visit estimated based on national averages.

Cost Savings: California Medicare

Est. Direct out-of-pocket Lab Cost Savings for California Medicare



10-year aggregate savings of $12.1 billion

Source: CMS.gov, KFF.org and Theranos estimates

Specialized for Every Specialty

Theranos is a new standard in lab testing that can help every practice. And we offer even more specialized tools for patients with specific needs.

Oncology

With Theranos, patients can get all the necessary frequency with less trauma. Our micro-samples have lowers the risk of anemia and other secondary effects of large volume draws.

Pediatrics

When you're caring for the tiniest patients, even a simple blood draw can be the biggest obstacle. But since we only require tiny drops, our tests are less traumatic, giving you more smiles and fewer tears.

Geriatrics

With Theranos, you can process samples from patients with collapsed veins without the discomfort they go through now. No more searching for veins. No more needle draws from the wrinkled back of the hand.

Same Tests, a Whole New Approach

The actionable information you need,
1/1,000 the size of a typical blood draw.

Theranos runs any test available in central laboratories, and processes all sample types.

All tests match existing reimbursement codes.

Theranos provides the highest level of oversight, automation, and standardization in our pre- and post-analytic processes, ensuring the highest levels of accuracy and precision.

Better Data from Fresher Samples

Theranos rapidly processes samples from our distributed PSC locations, allowing for analysis of key markers before their analyte decay rates affect result integrity.

Certain analytes decay rapidly in blood/serum, having half-lives of less than 12 hours. CRP for example has a half life of 7 hours.



A New Standard in Quality

The highest levels of accuracy.

By systematically controlling and standardizing our processes, Theranos offers tests with the highest levels of accuracy.

Theranos automates pre- and post-analytic processes, drastically minimizing human processing – the cause of the majority of lab test errors.

A New Standard in Quality

More precise trending.

By making it easier to precisely measure your body's information at the needed frequencies, we can help clinicians see small changes in test results as they emerge over time.

Theranos Systems are designed to help monitor chronic disease states, providing accuracy and precision over time through the standardization of our systems.

New Possibilities in Lab

Routine, Specialty and Esoteric Testing

- Comprehensive laboratory test menu available through Theranos
- Theranos runs any test available in central laboratories
- Theranos can process any sample type
- All tests match existing reimbursement codes
- With CLIA certification, Theranos is a nationally accredited provider

Higher Quality Data

- **Variability among traditional labs prevents insight into:**
  - Early disease onset, progression, and regression
- **The unprecedented lack of variation with Theranos yields:**
  - Higher integrity data and longitudinal trending
  - Earlier insight into the onset/progression of disease
  - Reduction in unnecessary secondary procedures from results which currently show up as false positive results

Faster results. Faster answers.

Theranos' micro-sample analysis is performed at amazing speeds, so we can report results faster than previously possible.

Data reported in high quality and in real-time becomes actionable information for improved decision making.

A Better Way to See Results

Results are conveniently accessed through theranos.md, our secure digital hub that organizes all your results, or accessed through traditional methods.

Results are reported in easy-to-read graphs, allowing for better visualization of test data in a new, informative way.

Predictive Insight: Disease Progression

Robust studies have shown that more frequent sampling on a low variability platform allows characterization of trends that cannot be seen when patients come into the clinic for blood draws less frequently and run in traditional labs.

Variability in M30 and M65 Pre-dose Levels (5-7 day gap between 2 pre-dose samples)



Time series: chemo-sensitive solid tumor and M30 M65 trends



Comprehensive Testing Across Methodologies

Auto-Reflex Testing

When clinicians order tests with Theranos, they can specify follow-on tests to run automatically on the same sample if certain tests are out of range.

This saves patients another trip to the lab, avoids prophylactic decision-making and unnecessary prescriptions, and helps clinicians properly diagnose conditions sooner than they would be able to with conventional processes.

An Entirely New Lab Experience

Theranos Information Systems

Theranos Information Systems facilitate real-time eligibility, authorization, authentication, information transmission, and billing

All data is transmitted to physicians through a secure customized portal, secure fax, and/or integration with EMR/LIS systems

Data visualization tools and front and back-end decision support applications support actionable interpretation of results

Providers and partners will have a customized portal for real-time access to data, analyses, and clinical decision support based on dynamic, individual patient data

Theranos Laboratory Market

- The US laboratory market is a $180 billion/year market and growing.
- On average, every American runs blood tests >3 times a year.
- The current largest traditional retail laboratory, which only operates in a small percentage of the total lab testing market, processes more than 151 million test requisitions.
- Replaces old infrastructure with new.
  - Infectious and chronic disease infrastructure.
- Increases traffic to retail stores and pharmacies.

Theranos Infrastructure

National retail footprint, hospital, and health plan partnerships throughout the United States for an unprecedented infrastructure which exceeds that of any retail laboratory in today's market.

Medicaid partnerships with states across the country regarding the exceptional impact on healthcare delivery and cost reduction.

Medicare partnership at the federal level focusing on improvements in delivery of services and Medicare cost reduction.

Theranos' Footprint Upon National Deployment: Theranos Wellness Centers in Walgreens



Theranos Wellness Centers

Walgreens & other retail pharmacies

Theranos' Footprint at retail:

Theranos Wellness Centers are located within a smaller radius from the patient, and open longer hours than currently available

Theranos has more Wellness Centers than any lab provider in CA

Convenience is offered at an unprecedented value

	1 mile	3 miles	5 miles
theranos	> 95%		
Current largest independent laboratory	9%	45%	69%
Current 2nd largest independent laboratory	7%	35%	56%

Theranos Wellness Centers

Theranos is introducing groundbreaking new spaces that transform the way patients and clinicians think about lab tests.

Theranos Wellness Centers are designed to make the patient experience as easy and comfortable as possible.

By giving people an easier way to get their lab testing done, they are more likely to be compliant with clinician lab orders.

Theranos Wellness Centers

Theranos Wellness Centers

Theranos Wellness Centers

Convenient Results 24x7

Theranos Wellness Centers are open 24 hours per day, 7 days per week

- 3x more operating hours per week than any national lab provider
- Painless patient experience any time of day
- Significant economic impact in reduction of physician office visits
- Better compliance yields better care



Seamless Integration with Physician Practices

Send samples to us.

You can send us samples using your smallest collection containers. Just sign up and we'll help you register and arrange courier/delivery options.
Get started here ›


theranos
1601 S California Ave • Palo Alto, CA 94304
PATIENT INFORMATION
Name (Last, First MI)
Address
City
State
Zip
SSN
DOB
Policy No
Bill to
Relationship to Insured

Send patients to us.

Or **download our lab order form*** and send your patients to our convenient Theranos Wellness Centers. Sign up today and we'll get you set up.

* valid NPI number required

Physicians can choose between sending patients to our convenient Theranos Wellness Centers, or drawing samples in their office or facility.

Theranos accepts all paper lab order forms in addition to offering our own form.

Theranos Hospital Partnership Benefits

- Theranos technology provides the opportunity for hospitals to significantly reduce costs of lab services
- Theranos' platform can be made accessible to employed and affiliated hospital physicians
- Theranos can provide testing services for all send-out tests while reducing the cost of testing services for the hospital
- Collection of small blood samples improves patient experience and reduces hospital labor costs
- Improvements in lab infrastructure create a significant differentiator for hospitals by providing greatly improved patient experience (notably pediatrics, geriatrics and oncology)

Recent Press

BBC WORLD NEWS

GlobalBiz: Health Technology

FORTUNE

This CEO is Out For Blood

Forbes

Bloody Amazing

USA TODAY

Change Agents: Elizabeth Holmes Wants Your Blood

FOX BUSINESS

Theranos CEO on Company's Blood Testing System

THE ARIZONA REPUBLIC
azcentral.com

Health-care Company to Open SkySong Operation

Recent Public Appearances

ASPEN IDEAS FESTIVAL 2014

Aspen Ideas Festival 2014

June 25: "Personalized Medicine: The Future is Now"

Moderator

Elliot Gerson, EVP of Policy and Public Programs, International Partners, The Aspen Institute

Speakers

Elizabeth Holmes, Founder & CEO, Theranos
Margaret Hamburg, Commissioner, FDA
Harvey Fineberg, President, Institute of Medicine

Theranos Headquarters: Palo Alto, CA

Theranos Facilities: Newark, CA

Theranos Facilities: Arizona

Scottsdale

SkySong

Recent Feedback

- "I don't have insurance and have to pay cash for everything. No one can ever give me a quote or a fixed price. Theranos and their transparency is so unusual " – **Customer at 6128**
- "I went to Lab Corp and was stuck 16 times before I came to Theranos. I am incredibly pleased and will never go anywhere else to get blood drawn" – **Customer at 5222**
- "Theranos is not only just ten minutes away from my house, but their prices are amazing, too" – **Customer at 3464**
- "I am a diabetic and have to have lab work done every two weeks. Last month, I paid $500 out-of-pocket at LabCorp. The prices and the finger stick change my life" – **Customer at 11610**
- "I am normally a very hard venous stick, but I didn't feel a thing with the finger stick. This is amazing" – **Customer at 11182**
- "I have a high-deductible plan and usually have to pay $391 for lab work. Today, with Theranos, I paid 54" – **Customer at 4139**
- "Last time I got billed for my tests at another lab it was $627, at Theranos is was $104" – **Customer at 4139**

Recent Feedback (continued)

- "I am so glad my doctor told me about Theranos. Last time at Sonora Quest I paid over $900" – **Customer at 3049**
- "I am not a big fan of Quest and my physician highly recommended Theranos. This was perfect, especially because I pay out-of-pocket" – **Customer at 4046**
- "I usually go to Lab Express to have my lab work done. When I go there it costs me $140, with you, it costs me $17" – **Customer at 3464**
- "Not only was the finger stick easier for my daughter (11 years old), but we're uninsured and your prices are great" – **Customer at 3464**
- "I wish I would have known about your services sooner; I would have saved a ton of money. I get tests done every three months" – **Customer at 5453**
- "I am very happy Theranos is inside Walgreens; it's convenient. Plus, I get off work at 4 PM and other labs close their doors at 3:45 PM. Theranos has great hours of operation" – Customer at 4139
- "I am very happy Theranos is inside Walgreens; it's convenient. Plus, I get off work at 4 PM and other labs close their doors at 3:45 PM. Theranos has great hours of operation" – **Customer at 4139**

Recent Feedback (continued)

- "I usually have to ask for a ride to get my blood work done, but with Theranos, I can conveniently get my lab work done without asking for a ride" – **Customer at 4139**
- "Our six year old son had a great experience today because of how well the Theranos Phlebotomist handled things" – **Customer at 4139**
- "This was quick; normally I wait for hours at Quest" – **Customer at 4046**
- "I'm uninsured and typically pay $70 more at Fit Health Care Clinic than I paid today at Theranos. Other places must be in a racket. I am coming here from now on" – **Customer at 3464**
- "I have been putting off my lab work for a year because another lab quotes me $1,000 for these tests. Today's visit cost less than $100 for me" – **Customer at 3464**
- "This was much easier than any other lab experience I have had, all because of the finger stick" – **Customer at 6128**
- "My physician sent me here because if I did the tests at his lab it would cost me $300 and the physician was going to have to break the tests up because of the costs. I was able to get all of the tests done at once, since it only costs me $20 here" - **Customer at 5453**

Recent Physician Feedback

"This has literally has brought some of my patients to tears....I see a lot of uninsured patients and they do not get their labs unless I force them...this has changed my patients lives. Our office administrator only wants us to use our in our house lab SQL...but we are rebels here we do what is best for our patients and that is Theranos" – **Dr. Stephen Bescak, Family Medicine**

"You guys are changing the world and I'm having so much fun talking about it!" – **Dr. Joseph Prendergast, Endocrinology**

"Well, Theranos is the Walmart of laboratories - you are on every street corner and you are pushing your competitors to do what you do, push pricing down. Most will not want to play with you and are probably running scared. Good for Theranos for finally doing what is right - like Walmart you will be a household name known for thinking of the customer first." – **Dr. John Elliott, OBGYN / Maternal Fetal Medicine**

Recent Physician Feedback (continued)

"I went to the lab and just kept checking things off to be tested because it was so inexpensive. I got almost 10-15 labs for under $100 and the phlebotomist was great. The easiest draw I have had. Everything was really clean and calming, I was almost in a trance with the music, water and tvs. A really cool experience. Did I just say that about labwork? Wow!" – **Dr. Michael Fahmy, Anesthesiology / Internal Medicine**

"LabCorp came in and dropped their prices to match yours; I asked them why can you suddenly offer prices like this now and not years ago?!?!" – **Dr. Ashwin Patel, Internal Medicine**

"This is truly a patient's life changing service. I see so many patients that are self pay and we cannot properly diagnose them because they can't afford their labs....I am SO excited that Theranos has developed this new technology, convenience, and price points...I can see this being my lab of choice for everyone that needs blood work. Let's try to get more FP and IM on board so that all of our records are similar....let's do this together" – **Dr. Nadeem Hussain, Cardiology**

Recent Physician Feedback (continued)

"The experience I had was truly amazing! I had sent a few patients to Theranos before I went for my own labs and now I will be sending all of my patients to Theranos." – **Dr. Kirsten Correia, Naturopath**

"You guys are perfect. The patients love it - the convenience, the price and less blood! The results have been prompt and accurate. I love it!" – **Dr. Petran Beard, DO / Preventative Medicine**

"I've been delaying getting lab work done; this is such an easy option I'm excited to try it out myself." – **Dr. Bowne, Family Medicine**

"Patients tell us all the time how much they love the convenience." – **Dr. Lopez Jr, Family Medicine**

Physician directed testing

theranos

theranos means a new paradigm of diagnosis.

Our mission is to make actionable information accessible to everyone at the time it matters most.

Theranos has been certified as a high-complexity CLIA lab since 2011

tiny sample



clinical data

tests/panels

results

access

pricing

experience

workflow

access to actionable information at the time it matters.

Access

- Micro-samples
- Unprecedented affordability
- Convenient locations
- Night and weekend hours
- Fast results

Actionable information

- High-complexity CLIA certified laboratory
- Automated processes and standardized tests
- Automated reflex testing
- Screenings

representative clinical data.



representative clinical data.



representative clinical data.



representative clinical data.

HCV Antibody Sensitivity and Specificity

Theranos v Reference Lab Contingency Table

Theranos	Reference Lab		
	Positive	Negative	Total
Positive			153
Negative			99
Total	149	103	252

Predictive Values Summary

Positive Predictive Value	96%
Negative Predictive Value	98%
Detection Prevalence at	59%



automated reflex testing.

- Order reflex tests directly from the Theranos lab order form
- Immediate follow-on testing across test methodologies available for values that are out-of-range
- Rapid and comprehensive diagnostics from a single lab visit



our impact.

"My daughter is recovering from a hypothalamic brain injury that has caused her the need to have her blood tested for Sodium, Calcium and Potassium on a very frequent basis. In addition she is borderline anemic. Besides taking her precious blood for this test, the delay in obtaining results is frustrating as we need to adjust her medication based on it. Your ability to test these parameters on such a small amount of blood is exactly what she needs."

— EMAIL FROM ELLEN IN CALIFORNIA

access for everyone.

Contracted with: Medicare/Medicaid and Commercial plans

Universal pricing regardless of insurance status at rates that are lower than the best contracted rates nationwide.

convenient locations.

early morning, evening and weekend hours. at retail for the first time.

APACHE JUNCTION
55 W Apache Trail
Mon-Fri 6a-10p
Sat-Sun 8a-6p

CAVE CREEK
29660 N Tatum Blvd
Mon-Fri 8a-10p
Sat 9a-6p Sun 10a-6p

CHANDLER
1975 S Alma School Rd
Mon-Fri 7a-10p
Sat 9a-6p Sun 10a-6p

FOUNTAIN HILLS
16415 E Palisades Blvd
Mon-Fri 8a-10p
Sat 9a-6p Sun 10a-6p

GILBERT
785 S Cooper Rd
Mon-Fri 6a-10p
Sat-Sun 8a-6p

GLENDALE
4965 W Bell Rd
Mon-Fri 6a-10p
Sat-Sun 8a-6p

GOODYEAR
3361 N Litchfield Rd
Mon-Fri 6a-10p
Sat-Sun 8a-6p

MESA
9230 E Main St
Mon-Fri 8a-10p
Sat 9a-6p Sun 10a-6p

1130 W Southern Ave
Mon-Fri 9a-9p
Sat-Sun 10a-6p

PEORIA
9050 W Union Hills Dr
Mon-Fri 6a-10p
Sat-Sun 8a-6p

9040 W Peoria Ave
Mon-Fri 8a-8p
Sat-Sun 9a-5p

PHOENIX
7000 N 16th St
Mon-Fri 6a-10p
Sat-Sun 8a-6p

7606 S 7th St
Mon-Fri 8a-10p
Sat 9a-6p Sun 10a-6p

204 E Bell Rd
Mon-Fri 6a-10p
Sat-Sun 8a-6p

8301 W Camelback Rd
Mon-Fri 9a-9p
Sat-Sun 10a-6p

3402 N Central Ave
Mon-Fri 6a-10p
Sat-Sun 8a-6p

3960 E Chandler Blvd
Mon-Fri 6a-10p
Sat-Sun 8a-6p

3450 W Dunlap Ave
Mon-Fri 6a-10p
Sat-Sun 8a-6p

5101 W Indian School Rd
Mon-Fri 6a-10p
Sat-Sun 8a-6p

3605 E Thomas Rd
Mon-Fri 6a-10p
Sat-Sun 8a-6p

2415 E Union Hills Dr
Mon-Fri 6a-10p
Sat-Sun 8a-6p

3431 W Union Hills Dr
Mon-Fri 9a-9p
Sat-Sun 10a-6p

4249 W Glendale Ave
Mon-Fri 6a-10p
Sat-Sun 8a-6p

SCOTTSDALE
6501 E Greenway Pkwy
Mon-Fri 8a-10p
Sat 9a-6p Sun 10a-6p

3420 N Scottsdale Rd
Mon-Fri 6a-10p
Sat-Sun 8a-6p

7011 E Shea Blvd
Mon-Fri 6a-10p
Sat-Sun 8a-6p

SUN CITY WEST
19003 N R H Johnson Blvd
Mon-Fri 7a-8p
Sat-Sun 9a-5p

TEMPE
2000 S Mill Ave
Mon-Fri 8a-10p
Sat 9a-6p Sun 10a-6p

QUEEN CREEK
333 E Hunt Hwy
Mon-Fri 8a-10p
Sat 9a-6p Sun 10a-6p

convenient locations.



affordable pricing. for everyone.

Free T3 + Free T4

theranos	$18
other lab 1	$100
other lab 2	$212

affordable pricing. for everyone.

affordable pricing. for everyone.

PT/INR

theranos	$3
other lab 1	$18
other lab 2	$25

affordable pricing. for everyone.

affordable pricing. for everyone.

Vitamin D

theranos	$20
other lab 1	$90
other lab 2	$247

affordable pricing. for everyone.



affordable pricing. for everyone.

Chlamydia/Gonorrhea

theranos $35

other lab 1 ..... $170

other lab 2 ..... $246

affordable pricing. for everyone.



affordable pricing. for everyone.

CBC, CMP, Lipid, TSH, VitD

theranos	$54
other lab 1	$107
other lab 2	$432

affordable pricing. for everyone.

unprecedented price transparency.

www.theranos.com/test-menu

prices listed for every test.



more affordable. under any plan.

C peptide – CPT 84681 out of pocket

theranos ..... $6 (40% co-insurance)

other lab ..... $11 (20% co-insurance)

more affordable. under any plan.



our impact.

"I've actually used Theranos as a patient myself and was thoroughly impressed by how painless the procedure was and how quickly I got an answer to my lab values. Not only as a clinician, but as a patient, I've found it to be simply amazing."

— DR. DARREN PHELAN IN CALIFORNIA

every Theranos test begins with you, the physician.

1) Fax any lab order form to Theranos
2) Direct your patients to the nearest Theranos Wellness Center.
3) Receive your patients' results in less than 48 hours on average.

EMR integration.

Quick integration with any EMR provider, platform, version.

tools for your patients.

lab order form with pricing and locations

tear away with instructions and locations



tear away (back)

a Theranos standing order example

STI

a Theranos standing order example

cell counts

a Theranos screening example



Hepatitis C

hepatitis C prevalence: Arizona.



- It is estimated that 1 in 12 people in Arizona are either HepB or HepC positive.
- ~40,000 people with HCV in Arizona (~1/3 of the infected population) do not know they are infected.
- Due to the current economic situation and budget issues there is no free state funded hepatitis testing in Arizona. – Arizona Department of Health Services

http://www.azdhs.gov/phs/oids/hepc/index.htm

HCV Ab Screen cost comparison.

HCV Ab	HCV Ab
theranos	$10
other lab 1	$47
other lab 2	$118

HCV Ab + confirmatory HCV RNA, Quant cost comparison.

HCV Ab + Confirmatory	HCV Ab	Reflex HCV RNA, Quant.	Total Screen
theranos	$10	$29	$39
other lab 1	$47	$464	$511
other lab 2	$118	$362	$480

HCV Ab Screen cost comparison.



HCV Ab + confirmatory HCV RNA, Quant cost comparison.



HCV diagnostic algorithm.



http://www.cdc.gov/hepatitis/hcv/PDFs/hcv_flow.pdf

Exemplary Pharma
Partner Reports

theranos

Exemplary Reports From Pharmaceutical Partners

CONFIDENTIAL

Theranos Angiogenesis Study Report

Pfizer, Inc.

Document Outline:

- Introduction to Theranos
- Background on Theranos Studies
- Economic Impact of Theranos Systems to Pharma
- Angiogenesis Program Overview
  - Study design
- Theranos System Overview
  - Specifications
  - Theranos System Performance
- Theranos Field Study
  - Field Performance Overview
  - Trial Data
  - Evaluation of time course results from individual patients
  - Review of generated data, in aggregate by patient ID, sex, cancer type, treatment, etc.
  - Integrated patient information, including date and time of monitoring, medication received, self evaluation of overall health status of each patient and other clinical data in a comprehensive format
  - Assessment of the technical performance of the Theranos System
    - Data transmission % success and mode of transmission used
    - General performance information as logged via the Customer Care line
    - Assessment of patient compliance with protocol
  - Summary of patient and clinical staff assessment of the Theranos System and the Client Solutions team via end-of-study surveys
- Conclusions
  - General
  - Technical
  - Economic

Introduction to Theranos:

Accurately, rapidly, and effectively profiling the efficacy dynamics of a therapy in clinical studies is an unmet need that has long challenged the conventional blood testing infrastructure.

Theranos has demonstrated in clinical studies that more frequent longitudinal time-series measurements on fresh whole blood samples with a multiplexed platform that eliminates the noise (and inability to accurately characterize very broad dynamic ranges) of conventional tests is imperative to effectively characterizing physiological changes and the efficacy of any intervention.

Theranos' wirelessly integrated data analytical system allows for 'baseline' profiles of pathway dynamics to be created and updated automatically as data is generated in the field. If needed, analyte selection or frequency of sampling can be adjusted at any time during the study based on the data coming in.

In future studies within a given indication, the data analytical infrastructure can be used for predictive modeling wherein new patient data can be indexed against the stored baseline profiles for earlier reads on efficacy dynamics and dose-response.

Background on Theranos Studies:

Every day gained in getting a new brand to market can be measured in millions of dollars.

Time is a major factor of cost of development of a new drug. For years the pharmaceutical industry has worked to drive every day possible out of the development process, and has reached a point where the physical limitations around the timelines for statistically significant data acquisition primarily determine the time to market.

Theranos Systems revolutionize those timeline constraints by enabling instant access to higher quality data and exponentially faster reads on efficacy and safety dynamics from the initiation of clinical trials. In doing so, Theranos is laying the foundation of a new growth model for pharma.

Theranos Systems radically impact revenues and growth on new and existing drugs in ways that were previously not possible:

- Faster approvals and studies - Immediate access to results enables immediate decision making and planning; early reads on efficacy dynamics and dose optimization for sub-populations through more comprehensive longitudinal PK/PD profiling
- Reimbursement and differentiation - Concrete reads on efficacy dynamics and visibility into mechanisms of action to optimize compounds dynamically
- Rapid access to multiple markets pre and post-approval - early reads on efficacy through trends in the change in rate of key markers allow for rapid label expansion
- Amelioration of safety concerns – more accurate reads on actual pathway dynamics enable rapid optimization where beneficial and delineation of patient sub-populations

Economic Impact of Theranos Studies to Pharma:

Based on Theranos' previous experience, predictive modeling and more comprehensive longitudinal profiling has resulted in the demonstration of meaningful dose-response and efficacy dynamics profiles in 6 month timeframes where the conventional infrastructure took two years and was still not able to generate hard correlations. An 18 month time-savings, not to mention the ability to gain insight into methods for optimization for label expansion, can conservatively be equated to hundreds of millions of dollars gained. With industry estimates at $1-3M a day for the value of each day gained in time to market, even 6 months saved ranges between $180M and $540M in return on investment.

Equally, once the infrastructure has been implemented, future studies are requiring about 25% fewer patients, reducing the patient costs, number of sites required, assay development, reagent screening, and infrastructure costs for shipping and processing samples through ambulatory point-of-care monitoring.

Overall savings on 6 month trials once the data analytical infrastructure has been established have averaged 50% of the cost of running an equivalent trial through the conventional infrastructure, further saving millions of dollars. As the data analytical engine evolves after the first 6 month study, costs are further reduced in each follow-on study, covering the cost of Theranos infrastructure and units many times over.

Ultimately though, the greatest economic return on investment lies in the ability to expand percentage market ownership through visibility into pathway dynamics that enables rapid characterization of responder populations in ways previously not possible. This capability enables

commercialization of 'targeted blockbusters' by redefining a company's historical success rate in realizing the target product profile of each drug once it hits the market.

Angiogenesis Program Overview:

The primary objective of the present program was to demonstrate the functionality of Theranos Systems in such a way that future studies could fully leverage the power of comprehensive longitudinal time-series profiling for rapid compound optimization and development.

For this program, Theranos was asked to develop multiplexed point-of-care assays for VEGF and PlGF for use in monitoring patient pharmacodynamic response to anti-angiogenesis therapies. Because the development of VEGFR2 in that multiplex was desirable as a tool for use in future studies, Theranos developed the assay and included it in the point-of-care multiplex.

In this program, Theranos validated not only functional equivalence, but superior performance specifications of the Theranos multiplex to each of the respective 'gold-standard' kits.

An Interim Report on Assay Development was submitted to Pfizer in Q2 '07 upon successful completion of assay development.

As planned for at the interim update meeting with Pfizer, the first patient began participating in the study in July of 2007. In order to fast-track the program timeline, Theranos contracted an independent site - Tennessee Oncology Center.

Enrollment of Sutent patients at this site was very slow; from the time patient screening began (early 2007) and after discussions with respective members of the Pfizer team, the protocol was revised several times to increase the frequency of monitoring but reduce the total number of patients and shorten the monitoring cycles per patient. Likewise, enrollment criteria were broadened to include patients on other therapies with whom trends in the relevant markers could also be profiled.

In doing so, statistical significance in meeting the study goals could still be ensured. Multiple IRB submissions were filed. Final IRB and Informed Consent Forms were included in two interim update reports sent to Pfizer.

Goals of Study:

1. Generate preliminary data on VEGF and PLGF trends in cancer patients while assessing the use of the Theranos System in the hands of clinicians and patients.
2. Obtain feedback and recommendations from clinical staff.
3. Assess the use of the Theranos System in the hands of ambulatory patients at home.
4. Assess the Ambulatory Bioinformatics Communications System[1] including the physician and patient web portals as well as the data reports generated.

Study design:
Patient screening began in January 2007, once the final site was selected, enrollment began. In July of 2007, the first patient was enrolled in the trial. This trial consisted of very ill late-stage (4th line) cancer patients with various tumor types receiving a variety of therapies at the Sarah

[1] The Ambulatory Bioinformatics Communication System (formerly known as ABCS) was rebranded as TheranOS, the Theranos Operating System.

Cannon Research Center at Tennessee Oncology (TNONC) in Nashville, Tennessee. The patients in the study typically resided in very remote locations across the eastern US. Almost all patients were not computer literate, and most were from low income families, unable to afford private telephone service.

The Theranos angiogenesis monitoring system was evaluated for clinical efficacy and as a means of more accurately and effectively monitoring cancer therapy and the progression of solid tumor cancers from a mechanism-of-action perspective. 32 patients were enrolled. Various cycles of therapies were monitored as well as physical changes in tumor size.

Four of the patients retracted consent to the study, three of them due to family problems and one due to mental and physical instability. Thus, Theranos increased the targeted enrollment number to ensure that the goal of demonstrating performance across significantly significant patient numbers would be met. That goal has now been achieved. To realize the goal, some patients had extended (60 day) monitoring periods.

Since Theranos has the ability to continue monitoring patients under the existing IRB and given the power of some of the correlations which are becoming apparent, Theranos may continue monitoring those patients for an extended period of time.

Enrollment was unpredictable and slow. All installations and shipments completed for this study were done on-demand with less than 24 hours. As part of the installation procedure, Theranos' client solutions team has performed at-home installations and pick-ups for many weak patients.

For each patient, a total of up to 14 time points were collected during the month-long analysis period, 3-4 time points taken at the clinic and the other 10-11 time points taken in-home. Both finger-stick and venous samples were taken during each clinic visit, while only finger-stick samples were run in-home. The venous draw samples were run on the Theranos System in the clinic at the time of the draw; these samples were also processed so that the plasma and/or serum was analyzed using a reference method.

Venous samples were processed using reference methods and provide an archive of 41 anti-coagulated plasma and serum samples which were frozen and have subsequently been analyzed at Theranos.

Theranos System Overview:

The Theranos System is comprised of consumer-oriented readers, single-use cartridges containing assay chemistry and controls, and a data collection system that communicates through cellular networks with the instrument to provide assay protocols and to compute and display results.

The steps required of a new patient are to 1) take the machine out of the box and 2) plug it into a power source. The touch-screen then walks each patient through the process of poking his/her finger, depositing blood into the cartridge, and placing the cartridge in the reader drawer. The instrument then processes the assays and sends the data through the cellular network in real-time to a secure web-portal.

Theranos Systems allow for quantitative, multiplexed longitudinal time-series measurements to map correlations between the rate of change of blood-borne markers over time to surrogate and clinical end-points.

Specifications:

- Designed for at home use. Can also be used in physician's offices, ICU, and laboratories.
- Multiplexed measurement of biomarkers.
- Customizable for different/new assays on demand.
- Average 6 measurements per cartridge
- Serial measurements to comprehensively profile pharmacodynamic response through trends
- Runs fresh whole blood, plasma or serum samples
- Finger-stick – small sample size
- Mix and match selection of analytes on demand.
- Wide measurement range
  - pg/mLl – mg/mL (1 billion fold)
- High sensitivity
  - 0.2 pg/mL (2 parts per 10-billion)
- Analyte Recovery: ~100 %
- System CV post-calibration (inter-intra reader, cartridge, and assay): < 10 %
- On-board chemistry controls
- Factory calibration (no user calibration)
- Wireless communication of results to appropriate user through cellular network
- Proprietary algorithms to interpret time trend results

The existence of a technology infrastructure for home, real-time blood monitoring allows collection of information which cannot be obtained using conventional blood testing scenarios:

- Small sample (finger-stick) + more frequent sampling of a small subset of analytes enables:
  - Identification of appropriate analytes (greatly helped by more frequent sampling)
  - Earlier detection of efficacy and safety and acute problems so intervention (for example, dose modification or change in drug type) can be more effective
  - Convenience of monitoring through-out a time-course before an event
- Higher sample integrity; real-time sample analysis on fresh whole blood on a standardized platform which can be deployed at any location (world-wide) eliminates assay inaccuracy associated with commercially available tests performed on samples which are "old" by the time they are analyzed.
  - Elimination of erroneous results (caused by analyte instability) and inherent errors in data and patient correlations (caused by processing data at various contract locations)

For this study, an instrument was deployed in the home of each patient; four others were installed at the Cancer Center.

Three assays were performed simultaneously in multiplex by the system on a finger-stick sample of fresh whole blood. The analytes were Vascular Endothelial Growth Factor (VEGF), soluble VEGF receptor R2 (sVEGFR2, usually referred to as VEGFR2) and Placental Growth Factor (PLGF). Each assay was controlled using within-cartridge control measurements.

The system was calibrated at Theranos. Multiple cartridge lots were produced each with successively more clinically relevant specifications once samples were received from patients in the trial, as samples were not available during assay validation. Each lot was independently calibrated.

Traceability of calibration: Calibration is traced to authentic analytes dissolved at known concentrations in a plasma-like matrix. Calibration materials are prepared as mixed solutions of the three analytes. Assignment of calibrator concentrations is then made to values found for measurements of calibrators using reference assays.

System Performance Goals:

Assay	Reportable low pg/mL	Reportable high pg/mL	Precision CV, %
VEGF	20	10,000	10
VEGFR2	150	15,000	10
PLGF	5	1,000	10

Assay ranges achieved:
The goals for each assay's dynamic range were achieved. Due to the inability to receive samples for calibration at the beginning of the studies, the upper limit of calibration for VEGF was restricted to 3,000 pg/mL in the first cartridge lots, but then extended[2] to 10,000 pg/mL. For early cartridge lots the PLGF assay lower limit of sensitivity was 50 pg/mL. Therefore, many early results for PLGF were out-of-range low ("OORL"). Lots produced after receiving samples for calibration have reportable ranges below 20 pg/mL.

[2] All three assays have a linear dose-responses extending far above the highest calibrator used.

Specificity:
The specificity of the assays depends on the pairs of antibodies chosen for each assay. In the first instance, we rely on the antibody vendor information. Selected pairs are known to have good specificity in ELISA assays. Key issues for these analytes are (1) the structural relationship of VEGF and (2) the fact that VEGF binds to sVEGFR2. We have shown that the Theranos assay system is not affected by the presence of VEGF and VEGFR2 and PLGF in the same samples. In many patients in this study, the drug Avastin is used. This drug is an antibody that binds to VEGF. It is obvious that ELISA assays for VEGF (and perhaps VEGFR2) using antibody pairs are likely to be interfered with by Avastin. As documented below, Theranos assays for VEGF and VEGFR2 appear to function with minimal interference from Avastin. In contrast, the selected reference assay for VEGF is strongly interfered by Avastin.

Theranos System Performance:

Assay accuracy:
Accuracy has been evaluated by analysis of clinical samples. Two sets of samples have been used: (1) A set of 12 serum samples from cancer patients (obtained from a commercial vendor), (2) 41 archived serum and plasma samples from this study. Because Avastin was used to treat many of the patients in the TNONC study and this antibody strongly interferes with the reference method, we used the commercially available samples for VEGF assay evaluation.

Twelve serum samples were assayed (singlicate) in the Theranos system and in duplicate for the reference method with the following results:

VEGF: y (Theranos) = 0.785 x (reference) + 95.2; R^2 =0.99. Range 96 – 1985 pg/mL. One sample was rejected from the analysis giving very high results in the Theranos system and low results in the reference assay. Based on the study data, it seems likely this patient was being treated with the drug Avastin, which interferes with the reference assay.

Single cartridge clinical results



For VEGFR2, 39 TNONC samples were assayed in triplicate in the Theranos system and duplicate for the reference method. The results were: y (Theranos) = 1.29 x (reference) + 1004; R =0.83. Range 1015 – 9285 pg/mL.



For the initial PLGF samples analyzed by Theranos in the field and with the reference method the results fell mostly in the undetectable range of both methods. Once the Theranos calibration was re-optimized, values became detectable from 5-17 pg/mL in the out-of-range-low venous samples sent to Theranos.

A significant correlation was achieved during validation on normal serum samples from twenty pregnant women assayed in quadruplicate. They were analyzed on both the Theranos system and the reference R&D Systems kit. The following results were obtained: y (Theranos) = 1.26*x (R&D Systems); R = 0.96. The average within sample CV for the Theranos results was 9%. One sample (shown in pink) below gave discrepant results.



When the results for patients were segregated by trimester and averaged, the concordance shown below was found.



Effect of Avastin on the reference VEGF assay:
Comparison of reference and Theranos VEGF assay results for venous samples were not correlated. Many Theranos results were in the thousands of pg/mL where reference assay gave a low value. Since it was noted that many of the patients had been treated with Avastin which binds to VEGF, Theranos did a study of spike recovery for the reference method. VEGF (400 pg/mL) was added to each sample and the assay repeated. Results are shown below:

Avastin Present	VEGF average, pg/mL Ref	VEGF average, pg/mL Theranos
N	149	588
Y	136	8359

	VEGF spike recovery, %
N	66.5
Y	-1.3

It is evident that Avastin completely blocks the reference assay response. Presumably, Avastin binds at a site on VEGF close to or identical with that recognized by one of the antibodies used in the reference method. The reference assay thus responds only to free VEGF whereas the Theranos assay is not blocked and measures both Avastin-bound and free VEGF.

Assay precision:

Inter-Instrument Precision:
Venous samples from patients were run across four instruments.

Assay	Reportable low pg/mL	Reportable high pg/mL	Precision CV, %
VEGF	20	10,000	8.0
VEGFR2	150	15,000	7.3
PLGF	5	1,000	9.2

Precision in comparison to available reference methods was evaluated during calibration. Singlicate measurements from six instruments were used next to commercially available 'gold-standards'. Theranos adjusted the target range after obtaining clinical samples. Due to the superior performance characteristics of Theranos' assay next to commercial standards, obvious variances are seen where the reference methods report OORL.

Single lot calibration data:

Analyte	Range (pg/mL)	Average CV, %
VEGF (lot 3)	30 – 10,000	12.0
VEGF (lot 1)	30 – 3,000	10.0
VEGFR2 (lot 3)	1,000 – 10,000	4.8
VEGFR2 (lot 1)	50 – 800	17.6
PLGF (lot 3)	5 – 780	26.9
PLGF (lot 1)	50 – 800	9.1

Precision was also measured by analysis of the 41 archived clinical samples in assays and for VEGF 12 commercial samples.

Analyte	Range (pg/mL)	Average CV, %
VEGF	30 – 10,000	16.7
VEGF[3]	96 – 1985	5.7
VEGFR2	1,000 – 10,000	20.4
PLGF	5 – 780	28.7

Dilution linearity:

Data gathered during lot calibration.

VEGF, pg/mL	Recovery, %
10000	(100)
2970	102
990	95
297	105
100	109
30	105
10	101

[3] Commercial samples

VEGFR2, pg/mL	Recovery, %
10560	(100)
7920	92.9
5280	100.9
3960	104.8
2640	97.7
1320	100.8

PLGF, pg/mL	Recovery, %
780	100.0
312	87.6
156	102.8
47	106.3
16	92.4
5	99.4

For all assays, recovery was close to 100 % in the reportable range.

Limit of detection (LOD):
Data gathered during calibration. The LOD is defined at a 95 % confidence level.

Analyte	LOD, pg/mL
VEGF	< 20
VEGFR2	< 200
PLGF[4]	< 20

Theranos Field Study:

The system has been deployed to patient's homes and the TNONC study clinic and has downloaded protocols and uploaded data wirelessly. Some patients used direct telephonic communications (POTs modems) if they were worried about cell reception. Data for every patient has been profiled on a secure, Pfizer-specific server.

Field Performance Overview:

In this report we document results from:

- 27 patients (41% female and 59% male)
- 13 cancer types
- 38 Instruments
  - 27 instruments deployed to patients' homes

[4] Later stage cartridge lots

- 4 instruments deployed to the clinical site in Nashville, TN
- 4 updated instruments to replace the readers at the clinical site such that the latest design revolution is deployed at the site
- 3 were used to replace malfunctioning readers in the field (2 at clinic - one with communication issue, one mechanical due to user error; 1 at patient's home with mechanical issues from shipping)

• 445 cartridges (approximately 1300 assay results)
- This number includes cartridges run in-house on archived plasma as well as results gathered in-field

Data acquisition has proven feasible in the home setting. There were instruments in the field operating in extreme temperature conditions (from very hot, no A/C to A/C turned to the maximum) as well as in very diverse locations (from RV's to log cabins in the middle of forests), in remote, difficult to reach areas where poor cellular reception is prevalent.

The instruments have been deployed across three states, including Kentucky, Pennsylvania and Tennessee. As mentioned, typical turnaround time for installation and patient at-home test was less than 24 hours without notice.

In monitoring this multiplex of analytes at far greater frequency than ever before, considerable patient-response variation can be seen across different sub-patient populations, therapies, and cancer types.

When we look at the average results from each patient and the variation seen for each patient, it is evident that the patients vary drastically:

	VEGF Avg., pg/mL	VEGFR2 Avg., pg/mL	PLGF Avg., pg/mL
Maximum	13,584	6,317	410
Minimum	47.5	368	37.3

By evaluating sample statistics such as these, one can identify patients who are anomalous and who may benefit from therapy modification.

For example, of the 13 patients with colon cancer we see one subject with an average VEGF of 13,600 pg/mL and another with an average of 255 pg/mL whereas most of the patients had VEGF values quite closely clustered at 1000 - 5000 pg/mL. Similarly, we see some subjects who show very little variation in analyte values and others with wide variations presumably related to response (high or low) to therapy.

Trial Data:

The following raw trial data is included in the appended spreadsheet:

1. Clinic visit diagnostics (Patient characteristics and Clinical assay results)
2. Clinic visit pivot table (clinical results presented as a customizable pivot table)
3. Patient aggregate data (Compliance data, Result averages and CVs by patient and averages by cancer type)
4. All field analyte data results (from the Theranos system presented by patient in a filtered table format [sort-able])
5. Treatment data (drugs used and dosage)

6. Individual end-of-study results (patient evaluation of system)
7. Compilation and summary of end-of-study survey results
8. Data transmission statistics

Evaluation of time course results from individual patients:

The study data demonstrates that in a larger, statistically controlled study, where the endpoint is directly proportional with patient outcome, e.g., a RECIST Score, a correlation between analyte dynamics and patient response to treatment would be generated.

To showcase the ability to profile predictive correlations between treatment and response profiles, we selected data from two patients -- 14 and 12. Due to patient 14's clinic schedule (first figure below), we were able to collect data following multiple infusion dates, allowing limited statistical analysis to be performed that correlates analyte levels with treatment administration. The cross-correlation function (second figure below) looking at VEGF and VEGFR2 blood levels for patient 14 shows a positive correlation at a cadence of 3 data points. This coincides with the patient's weekly clinic visits during which the patient receives the Avastin infusions.



The change in rate of the parameters can be correlated to progress, seen again below in a correlation plot:



For patient 12 (first figure below), we observe an inverse correlation between VEGF and VEGFR2 blood levels. This suggests that the blood analytes behave differently with different drug treatments, pointing at distinct pathways of drug activity (second figure below).


SCP012
Analytes inversely correlated; daily Sorafenib
2500
2000
1500
1000
500
0
6/1/2008 0:00
6/6/2008 0:00
6/11/2008 0:00
6/16/2008 0:00
6/21/2008 0:00
6/26/2008 0:00
7/1/2008 0:00
7/6/2008 0:00
Date
VEGF
VEGFR2


tnonc12.vegf & tnonc12.vegfr2
Cross-Correlation
0.6
0.4
0.2
0.0
-0.2
-0.4
-0.6
-6
-4
-2
0
2
4
6
lag

For most patients analyzed, the sample size and sample numbers did not provide sufficient statistical power to derive a statistically significant conclusion but some clinical endpoint measurements were accessible to correlate analyte vectors and their rates of change with time to the patient's progression and response to treatment.

Patient average VEGF and VEGFR2 data by cancer type:

Patient ID	Cancer type	Main Treatment	Average VEGF (pg/ml)	Average VEGFR2 (pg/ml)
SCP001	Adenocarcinoma	Sutent	47.5	2592
SCP006	Breast Cancer	Avastin	2082	2662
SCP010	Breast Cancer	Avastin	2055	3040
SCP008	Breast Cancer	Sorafenib	98	1863
SCP021	Colorectal Cancer	Avastin	4677	3646
SCP027	Colorectal Cancer	Sorafenib	1093	4863
SCP029	Colorectal Cancer	Sorafenib	3612	5658
SCP003	Colorectal Cancer	Sutent	72	2798
SCP007	Colorectal Cancer	Avastin	3860	2350
SCP009	Colorectal Cancer	Avastin	1840	368
SCP022	Colorectal Cancer	Avastin	Patient dropped	N/A
SCP014	Colorectal Cancer	Avastin	1826	1634
SCP019	Colorectal Cancer	N/A	Patient dropped	N/A
SCP016	Colorectal Cancer	Avastin	3006	2143
SCP031	Colorectal Cancer	Avastin	13584	5463
SCP024	Colorectal Cancer	Sorafenib	255	1540
SCP028	Colorectal Cancer	Sorafenib	1274	6317
SCP023	Esophageal Cancer	Avastin	3145	2260
SCP030	Gastrointestinal Stromal Tumor	Sutent	889	2424
SCP012	Liver Cancer	Sorafenib	96	1253
SCP017	Lung Cancer	Avastin	3947	2111
SCP025	Melanoma	Avastin	5399	3294
SCP002	Neuroendocrine carcinoma	N/A	Patient dropped	N/A
SCP026	Ovarian Cancer	Sorafenib	Patient dropped	N/A
SCP020	Renal Cell Carcinoma	Sutent	368	883
SCP004	Renal Cell Carcinoma	Avastin	2316	1057
SCP011	Renal Cell Carcinoma	Avastin	3159	1911
SCP013	Renal Cell Carcinoma	Avastin	3908	770
SCP015	Renal Cell Carcinoma	Avastin	3031	1068
SCP018	Tongue Cancer	Avastin	1457	3074
SCP005	Unknown Primary	Avastin	3099	2980

As referenced, patients #2, #19, #22, #26 dropped out of the study for various reasons; therefore average values are not statistically significant for them.

For the patients in whom PLGF is consistently detectable we selected plots as shown below.





Patient monitoring times and quality of life by gender:

			Time of day when home monitoring was performed	Quality of life (as measured by on-screen survey)
Patient ID	**Cancer type**	**Gender**	**(on average)***	**(on average)***
SCP001	Adenocarcinoma	f	Morning	N/A (Survey was not yet deployed)
SCP006	Breast Cancer	f	Afternoon	7
SCP010	Breast Cancer	f	Evening	8
SCP008	Breast Cancer	f	Late Evening	7
SCP021	Colorectal Cancer	f	Noon-afternoon	8
SCP027	Colorectal Cancer	f	Afternoon	10
SCP029	Colorectal Cancer	f	Afternoon-Evening	not yet available
SCP003	Colorectal Cancer	f	Morning	N/A (Survey was not yet deployed)
SCP017	Lung Cancer	f	Evening	9
SCP026	Ovarian Cancer	f	N/A	N/A
SCP020	Renal Cell Carcinoma	f	Afternoon	6
SCP005	Unknown Primary	f	Afternoon	9

SCP007	Colorectal Cancer	m	Evening	7
SCP009	Colorectal Cancer	m	Late Evening	7
SCP022	Colorectal Cancer	m	N/A	8
SCP014	Colorectal Cancer	m	Morning	7
SCP019	Colorectal Cancer	m	N/A	N/A
SCP016	Colorectal Cancer	m	Evening	8
SCP031	Colorectal Cancer	m	Afternoon	not yet available
SCP024	Colorectal Cancer	m	Afternoon	9
SCP028	Colorectal Cancer	m	Evening	not yet available
SCP023	Esophageal Cancer	m	Morning	8
SCP030	Gastrointestinal Stromal Tumor	m	Morning	not yet available
SCP012	Liver Cancer	m	Afternoon	10
SCP025	Melanoma	m	Morning	9
SCP002	Neuroendocrine carcinoma	m	N/A	N/A
SCP004	Renal Cell Carcinoma	m	Noon-afternoon	10
SCP011	Renal Cell Carcinoma	m	Morning	9
SCP013	Renal Cell Carcinoma	m	Evening	10
SCP015	Renal Cell Carcinoma	m	Evening	7
SCP018	Tongue Cancer	m	Afternoon	5
* Actual time for each test point and diurnal variations of quality of life can be found online				

Patient compliance with optional on-screen questionnaire was approximately 86% (this number was calculated before the end of the study, therefore final compliance figures may change).

Patient clinical visit data by age:

Patient ID	Race	Smoking Status	Alcohol Consumption	Age	Weight (pounds)
SCP029	Caucasian	does not smoke now, positive history	None	36	179
SCP010	Caucasian	never smoked	monthly or less	45	165
SCP018	Caucasian	Smoke daily	None	45	181
SCP007	Caucasian	never smoked	None	46	213
SCP008	Caucasian	smoke occasionally	None	46	180
SCP002	Caucasian	never smoked	monthly or less	49	194
SCP016	Caucasian	smoke occasionally	monthly or less	49	167
SCP012	Caucasian	does not smoke now, positive history	None	53	190
SCP015	Caucasian	does not smoke now, positive history	None	53	174
SCP028	Caucasian	smoke occasionally	None	57	262
SCP001	Caucasian	does not smoke now, positive history	None	61	172
SCP027	African American	never smoked	None	62	167
SCP009	Caucasian	never smoked	None	63	221
SCP011	Caucasian	does not smoke now, positive history	monthly or less	63	305
SCP024	Caucasian	infrequent attempts (never developed a habit)	Every day	64	200
SCP023	Caucasian	never smoked	Every day	65	252
SCP005	Caucasian	does not smoke now, positive history	monthly or less	66	160
SCP021	Caucasian	smoke occasionally	monthly or less	66	198
SCP006	Caucasian	never smoked	monthly or less	68	163
SCP017	Caucasian	does not smoke now, positive history	Every day	69	112
SCP013	Caucasian	never smoked	monthly or less	71	230
SCP020	Caucasian	never smoked	None	72	101
SCP026	Caucasian	never smoked	None	73	132
SCP031	Caucasian	does not smoke now, positive history	None	73	134.5
SCP025	Caucasian	does not smoke now, positive history	None	77	184
SCP014	Caucasian	does not smoke now, positive history	monthly or less	78	217.5
SCP022	African American	never smoked	None	82	178
SCP030	Caucasian	never smoked	None	83	182

Sample of patient clinical blood work by patient ID:

Patient ID	Avg. % Lymphocytes	Avg. Heart Rate	Avg. Total Bilirubin	Avg. Systolic BP	Avg. RBC
SCP001	33.4	67.7	0.7	129.3	3.2
SCP002	34.1	55.0	0.3	161.0	4.3
SCP004	27.8	64.7	0.5	144.7	3.2
SCP005	36.4	75.0	0.2	127.5	3.9
SCP006	29.5	100.7	0.3	112.7	4.3
SCP007	24.0	73.0	0.3	131.3	4.4
SCP008	23.7	84.0	0.4	124.0	5.1
SCP009	25.0	71.5	0.7	133.0	4.5
SCP010	45.3	74.3	0.9	137.8	4.5
SCP011	28.6	82.0	0.6	135.0	4.8
SCP012	28.3	75.5	0.7	122.0	4.0
SCP013	31.1	72.0	0.7	137.0	4.2
SCP014	40.2	81.5	0.4	125.3	4.0
SCP015	35.4	78.3	0.3	147.0	5.0
SCP016	18.0	75.3	0.3	131.3	4.9
SCP017	20.7	89.3	0.4	114.0	4.2
SCP018	23.4	70.0	0.3	133.0	4.8
SCP020	17.9	60.7	0.4	146.0	3.7
SCP021	36.5	91.0	0.4	130.0	4.8
SCP022	23.5	93.5	0.7	123.0	4.0
SCP023	26.3	107.7	0.7	119.7	4.7
SCP024	18.8	83.0	0.7	139.0	3.7
SCP025	33.5	94.0	0.3	143.0	5.2
SCP026	34.6	110.0	0.4	125.0	3.7
SCP027	9.5	70.0	0.7	119.0	3.7
SCP028	21.2	98.0	0.8	125.7	5.2
SCP029	32.6	90.5	0.6	122.8	5.1
SCP030	42.3	72.0	0.4	137.0	3.7
SCP031	16.7	70.0	0.4	145.0	4.3

All individual patient data was profiled as it was generated on the Pfizer-specific secure portal at www.theranos.com; raw data can also be found in the attached excel spreadsheet.

Server and Data Transmission

Approximately 361 cartridge results and 203 optional home surveys from the field were successfully transmitted to the Theranos servers. There were less than 5% transmission errors that required the readers to either retry sending the data or wait until they had a better connection to send the data. All data gathered in the field was transmitted to the Theranos servers. For the first two patients, on-screen surveys were not available. The number of surveys received is smaller than the number of cartridge runs due to the above as well as patients filling only one survey for each of their clinic visits (even though they ran two cartridges per visit). Once surveys

became available, each cartridge run also asked the user to complete an optional quality of life survey and compliance was very good.

Data distribution by transmission pathway to date		
Direct Internet Connection	Wireless-GSM	Traditional Phone line
5.6 %	90.7%	3.7 %

The only problem encountered with using GSM wireless phone technology was poor signal. The main reasons for poor cellular reception were: dense foliage, metal roofs and poor signal quality due to remote location. In one location (Stewart, TN), there was no cellular coverage at all; therefore the reader used the standard telephone line in order to connect to our servers and report data as it was gathered. All of this patient's logs were received by Theranos servers. In future studies, multiple network providers would be contracted for these areas.

Overall performance of the Theranos System based on Customer Care log:

The customer care line was available to patients 24 hours a day 7 days a week over the course of the entire study (July 07 to October 08). All calls were addressed professionally and all issues were resolved quickly, taking care to minimize the impact on patients and clinical staff.

The types of calls for which patients used the Customer Care line:

- Patient running low on supplies – the solution was to simply ship more of the needed supplies with overnight delivery to make sure patient had enough for the upcoming home tests.
- Patient not knowing how to turn machine on – the solution was to advise the patient over the phone on the procedures outlined in the setup sheet they received and to make sure they have the instrument up and running.
- Patient calling about scheduling an instrument pickup – solution was to schedule one of our representatives to pick up the machine or alternatively to have FedEx pick up the reader if patient was able to place it in the shipping container themselves.
- Patient called about blood transfer question – the solution was to advise the patient to leave the blood transfer device on a flat surface. If this solution was not sufficient, a new batch was shipped to make sure no capillary manufacturer defects were at fault.
- Patient called about instrument not recognizing cartridge – the solution was to ask patient to re-try and call back if problem persisted. The suspicion was that due to poor cellular signal the reader was unable to communicate, and by re-trying it would perform appropriately. There were no subsequent calls from patient.
- Patient called about instrument not being ready due to temperature – the solution was to ask patient to move reader away from A/C units and possible air currents. Patients had moved readers from initial installation location (one moved it to his RV, another into a really hot room) and the temperature extremes affected the readers' ability to maintain desired temperature. The Theranos readers are engineered to control temperature to eliminate variability associated with conventional assays.

The majority of systems deployed in the field performed their duties throughout the entire length of the patient monitoring schedule. One instrument had mechanical issues due to being misused; this happened during new personnel training at TNONC. The instrument was promptly replaced with a new instrument. Another failure occurred due to the instrument being damaged in shipping.

Although it performed its functions properly for the majority of the patient's schedule it eventually malfunctioned and was also promptly (~24 hours) replaced. Yet another issue was related to the cellular carrier not identifying the instrument. To expedite the process and assure that the clinic was adequately supplied it was decided to replace that instrument with one that was known to work. The problem was later resolved off-line.

Patient Compliance with protocol:

It is hard to estimate the patient compliance with the exact protocol due to the factors out of Theranos' control. In many instances patients re-scheduled their clinic visits and the new appointments were not communicated to us. At the onset of each patient's home monitoring they were provided with a tentative schedule which in many cases changed due to patient's need to travel or inability to keep scheduled appointments. With this in mind, we estimate that patient compliance with protocol was still very good, at approximately 96 % (measured as 80-120% of expected testing completed and received). Given the missing information, a much more accurate derivation would be possible.

Theranos System Assessment by Patients and Clinical Staff:

Patient end of study surveys were sent out to all participants. To date, 17 responses were collected from patients.

Summary of patients' assessment of the Theranos system:

- 88% of patients surveyed found the Theranos System easy to use; no patients found it "very hard" to use.
- 76% of patients found the written instructions to be very informative, with clear directions; 12% did not read instructions
- 91% of patients scored the training given by their Theranos representative either a 9 or 10 (10 being very good training)
- 76% of patients found the Theranos System takes little time to use (scores between 1 and 4 were tallied, with 1 = very little time and 10 = a lot of time)
- 100% of patients found the optional touch screen survey on the Theranos System easy to use, giving scores of either 8, 9 or 10 (10 = easy to use, 1 = hard to use).
- On a scale of 10 to 1 (10 = least painful, 1 = most painful), only one patient gave the blood drawing experience a score of less than 6. 59% felt almost no pain, scoring either a 9 or 10.
- 100% of the patients that responded to the survey gave Theranos Customer Support an excellent or very good rating
- For the majority of patients, the Theranos System worked very well. The major ways of solving the questions patients had were figuring it out on their own or calling the Theranos Customer Care line.
- In the follow-up survey, 100% of patients that responded said they received excellent or very good technical support over the duration of the study.
- Most patients said they prefer monitoring from home (scored 8 through 10) using the Theranos System; 25% were indecisive (scored 4 to 6) when asked whether they prefer going to the clinic or using the Theranos System; only two patients would rather monitor at the clinic.

From the interactions with clinical staff at Tennessee Oncology, the system was:
1. well received and

2. the client solutions team made a very positive impact on the clinical staff and patients through promptitude and professionalism.

Conclusions:

General:

1. The Theranos System performed with superior performance to reference assays while running in a complex ambulatory environment.
2. The existing Theranos support infrastructure enables on-demand home installation and patient training in extremely rural areas.
3. Patients preferred ambulatory monitoring to clinic visits and liked using the Theranos System.
4. Non-computer literate patients had no issues using the Theranos System.

Technical:

5. Inter-system accuracy is excellent and was demonstrated on a platform with superior performance specifications to reference methods.
6. Calibrations were updated with access to samples from the trial.
7. Good correlations were seen to various commercially available gold-standards.
8. Avastin does not block the Theranos assay.
9. The Theranos System can measure VEGF both free and bound to VEGFR2 and Avastin to better quantify dose-response.

Economic:

10. This 15 month study demonstrated the robust functionality of Theranos Systems. With this validation data, the technology can be applied to significantly cut costs and bring compounds to market faster:

11. More frequent sampling enabled better characterization of longitudinal time-series profiles of angiogenesis protein panels. More accurate insight of the change in rate of those panels over time enables significantly faster and earlier reads on efficacy dynamics.
    a. See efficacy dynamics trends and correlation to end-points in patient time-course profiles on the Pfizer web-portal at www.theranos.com.
12. Response profiles were seen in this study over 30 day intervals. Historically, these types of correlations have taken up to a couple years to demonstrate, or in some cases, were previously not demonstrable. This time gained facilitates rapid data generation for additions to a compendia and rapid label expansion of existing drugs. Equally, this approach can be used to fast-track approvals of key compounds and at the same time better optimize those compounds with better visibility to achieve the target product profiles.
    a. One of Theranos' pharma partners is publishing a report which estimates the increased time to market is valued at $1M per day – making every month quite substantial.
13. Through Theranos Systems, Pfizer will be able to reduce the number of sites, eliminate shipping costs for samples, processing costs, and analytical costs. Based on historical data, implementation of these systems will enable Pfizer to achieve ~50% cost savings over current study spending (previously demonstrated to be $15M of a $30M study budget). Equally, through better insight into pathway dynamics, Theranos is demonstrating the ability to reduce the number of patients required to show statistical significance in future studies by 30-50%.

Improving Probability of Success in PoC from 15% to 80% Results in eNPV of ~$202 million for Late Market Anemia Drug Entrant



Assumptions	
Peak year sales: $500 millions	P2 survival increase from: 15% to 80%
WACC: 8%	P3 survival: 57%
Contribution margin: 0%, 50%, 70%, 60%	Reg survival: 84%
R&D capitalization rate: 9.5%	P2 cycle time: 3.1 yrs
Revenue profile: Biologic	P3 cycle time: 2.8 yrs
	Reg cycle time: 1 yr

- Discounting cash flows to beginning of P2 results in expected **NPV difference of ~$202 million** by increasing probability of success
- Return on R&D investment for successful launched compound with the profile indicated would have **increased from -3.6% to +13% (an increase in return of ~10 percentage points)**

SOURCE: PharmaProjects; DiMasi et al. 2002 Journal of Health Economics; McKinsey analysis
WACC = weighted average cost of capital; LOE = loss of exclusivity ; POS = prob. of success

Intellectual property

Summary

theranos

Attorney Reference	Title	Type	Application Number	Filing Date	Country	Status
2000.102	RAPID MEASUREMENT OF FORMED BLOOD COMPONENT SEDIMENTATION RATE FROM SMALL SAMPLE VOLUMES	Utility: Provisional	61/930,432	1/22/2014	United States	Pending
2000.201	Rapid Measurement of Formed Blood Component Sedimentation Rate from Small Sample Volumes	Utility: Non-Provisional	13/945,147	7/18/2013	United States	Published
2000.501A	RAPID MEASUREMENT OF FORMED BLOOD COMPONENT SEDIMENTATION RATE FROM SMALL SAMPLE VOLUMES	Utility: Continuation-in-Part	14/319,644	6/30/2014	United States	Pending
2000.601	RAPID MEASUREMENT OF FORMED BLOOD COMPONENT SEDIMENTATION RATE FROM SMALL SAMPLE VOLUMES	Utility: PCT	PCT/US13/51143	7/18/2013	World Intellectual Property Organization	Published
2001.104	HIGH SPEED, COMPACT CENTRIFUGE FOR USE WITH SMALL SAMPLE VOLUMES	Utility: Provisional	61/930,462	1/22/2014	United States	Pending
2001.201	High Speed, Compact Centrifuge for Use with Small Sample Volumes	Utility: Non-Provisional	13/945,202	7/18/2013	United States	Published
2001.601	HIGH SPEED, COMPACT CENTRIFUGE FOR USE WITH SMALL SAMPLE VOLUMES	Utility: PCT	PCT/US13/51170	7/18/2013	World Intellectual Property Organization	Published
2002.105	IMAGE ANALYSIS AND MEASUREMENT OF BIOLOGICAL SAMPLES	Utility: Provisional	61/930,419	1/22/2014	United States	Pending
2002.106	IMAGE ANALYSIS AND MEASUREMENT OF BIOLOGICAL SAMPLES	Utility: Provisional	61/933,270	1/29/2014	United States	Pending
2002.107	IMAGE ANALYSIS AND MEASUREMENT OF BIOLOGICAL SAMPLES	Utility: Provisional	61/945,822	2/27/2014	United States	Pending
2002.201	IMAGE ANALYSIS AND MEASUREMENT OF BIOLOGICAL SAMPLES	Utility: Non-Provisional	13/951,063	7/25/2013	United States	Published
2002.202	IMAGE ANALYSIS AND MEASUREMENT OF BIOLOGICAL SAMPLES	Utility: Non-Provisional	13/951,449	7/25/2013	United States	Published

theranos

Attorney Reference	Title	Type	Application Number	Filing Date	Country	Status
2002.204A	IMAGE ANALYSIS AND MEASUREMENT OF BIOLOGICAL SAMPLES	Utility: Non-Provisional	14/167,964	1/29/2014	United States	Pending
2002.601	IMAGE ANALYSIS AND MEASUREMENT OF BIOLOGICAL SAMPLES	Utility: PCT	PCT/US13/52141	7/25/2013	World Intellectual Property Organization	Published
2002.602	IMAGE ANALYSIS AND MEASUREMENT OF BIOLOGICAL SAMPLES	Utility: PCT	PCT/US14/16962	2/18/2014	World Intellectual Property Organization	Pending
2002.851	Image Analysis and Measurement of Biological Samples	Utility: Foreign	102126668	7/25/2013	Taiwan, Province of China	Published
2003.104	SYSTEMS, DEVICES, AND METHODS FOR BODILY FLUID SAMPLE COLLECTION	Utility: Provisional	61/952,125	3/12/2014	United States	Pending
2003.105	Systems, devices, and methods for bodily fluid sample collection	Utility: Provisional	61/952,130	3/12/2014	United States	Pending
2003.201	Systems, Devices, and Methods For Bodily Fluid Sample Collection	Utility: Non-Provisional	14/020,435	9/6/2013	United States	Published
2003.202	SYSTEMS, DEVICES, AND METHODS FOR BODILY FLUID SAMPLE COLLECTION	Utility: Non-Provisional	14/214,774	3/15/2014	United States	Pending
2003.501A	SYSTEMS, DEVICES, AND METHODS FOR BODILY FLUID SAMPLE COLLECTION	Utility: Continuation-in-Part	14/320,471	6/30/2014	United States	Pending
2003.601	SYSTEMS, DEVICES, AND METHODS FOR BODILY FLUID SAMPLE COLLECTION	Utility: PCT	PCT/US13/58627	9/6/2013	World Intellectual Property Organization	Published
2003.602	SYSTEMS, DEVICES, AND METHODS FOR BODILY FLUID SAMPLE COLLECTION	Utility: PCT	PCT/US14/30792	3/17/2014	World Intellectual Property Organization	Pending

theranos

Attorney Reference	Title	Type	Application Number	Filing Date	Country	Status
2004.103	SYSTEMS, DEVICES, AND METHODS FOR BODILY FLUID SAMPLE COLLECTION, TRANSPORT, AND HANDLING	Utility: Provisional	62/011,023	6/11/2014	United States	Pending
2004.201	SYSTEMS, DEVICES, AND METHODS FOR BODILY FLUID SAMPLE TRANSPORT	Utility: Non-Provisional	14/098,177	12/5/2013	United States	Published
2004.602	Systems, Devices, and Methods for Bodily Fluid Sample Transport	Utility: PCT	PCT/US2013/000268		World Intellectual Property Organization	Published
2004.851	Systems, Devices, and Methods for Bodily Fluid Sample Collection	Utility: Foreign	102144582	12/5/2013	Taiwan, Province of China	Pending
2005.201	SYSTEMS, DEVICES, AND METHODS FOR BODILY FLUID SEPARATION MATERIALS	Utility: Non-Provisional	14/214,772	3/15/2014	United States	Pending
2006.201	SYSTEMS AND METHODS FOR RESPONSE CALIBRATION	Utility: Non-Provisional	14/035,762	9/24/2013	United States	Published
2006.601	SYSTEMS AND METHODS FOR RESPONSE CALIBRATION	Utility: PCT	PCT/US13/61485	9/24/2013	World Intellectual Property Organization	Published
2007.201	RAPID, LOW-SAMPLE-VOLUME CHOLESTEROL AND TRIGLYCERIDE ASSAYS	Utility: Non-Provisional	14/100,870	12/9/2013	United States	Published
2007.601	Rapid, Low-Sample-Volume Cholesterol and Triglyceride Assays	Utility: PCT	PCT/US13/74211	12/10/2013	World Intellectual Property Organization	Published
2008.201	ANTIBODIES AND ANTIBODY FRAGMENTS THAT BIND hCG, FERRITIN, LH, AND PSA	Utility: Non-Provisional	14/209,963	3/13/2014	United States	Pending
2008.601	ANTIBODIES AND ANTIBODY FRAGMENTS THAT BIND HCG, FERRITIN, LH, AND PSA	Utility: PCT	PCT/US14/29729	3/14/2014	World Intellectual Property Organization	Pending

theranos

Attorney Reference	Title	Type	Application Number	Filing Date	Country	Status
2009.201	RAPID MEASUREMENT OF VITAMIN D IN BLOOD	Utility: Non-Provisional	14/203,206	3/10/2014	United States	Pending
2009.202	RAPID MEASUREMENT OF TOTAL VITAMIN D IN BLOOD	Utility: Non-Provisional	14/203,239	3/10/2014	United States	Pending
2009.601	RAPID MEASUREMENT OF VITAMIN D IN BLOOD	Utility: PCT	PCT/US14/23825	3/11/2014	World Intellectual Property Organization	Pending
2010.201	ANTIBODIES AND ANTIBODY FRAGMENTS THAT SPECIFICALLY BIND HUMAN IMMUNOGLOBULINS	Utility: Non-Provisional	14/209,991	3/13/2014	United States	Pending
2010.601	ANTIBODIES AND ANTIBODY FRAGMENTS THAT SPECIFICALLY BIND HUMAN IMMUNOGLOBULINS	Utility: PCT	PCT/US14/29777	3/14/2014	World Intellectual Property Organization	Pending
2011.201	ANTIBODIES AND ANTIBODY FRAGMENTS THAT SPECIFICALLY BIND FLU VIRUS NUCLEOPROTEINS	Utility: Non-Provisional	14/210,022	3/13/2014	United States	Pending
2011.601	ANTIBODIES AND ANTIBODY FRAGMENTS THAT SPECIFICALLY BIND FLU VIRUS NUCLEOPROTEINS	Utility: PCT	PCT/US14/29797	3/14/2014	World Intellectual Property Organization	Pending
2012.201	ANTIBODIES AND ANTIBODY FRAGMENTS THAT SPECIFICALLY BIND CD14	Utility: Non-Provisional	14/210,046	3/13/2014	United States	Pending
2012.601	ANTIBODIES AND ANTIBODY FRAGMENTS THAT SPECIFICALLY BIND CD14	Utility: PCT	PCT/US14/29815	3/14/2014	World Intellectual Property Organization	Pending
2013.201	ANTIBODIES AND ANTIBODY FRAGMENTS THAT SPECIFICALLY BIND B12	Utility: Non-Provisional	14/210,059	3/13/2014	United States	Pending
2013.601	ANTIBODIES AND ANTIBODY FRAGMENTS THAT SPECIFICALLY BIND B12	Utility: PCT	PCT/US14/29834	3/14/2014	World Intellectual	Pending

theranos

Attorney Reference	Title	Type	Application Number	Filing Date	Country	Status
2014.201	SYSTEMS AND METHODS FOR MULTI-ANALYSIS	Utility: Non-Provisional	13/769,779	2/18/2013	United States	Published
2016.201	Systems and Methods for Collecting and Transmitting Assay Results	Utility: Non-Provisional	13/769,798	2/18/2013	United States	Published
2016.601	Systems and Methods for Collecting and Transmitting Assay Results	Utility: PCT	PCT/US14/16593	2/14/2014	World Intellectual Property Organization	Pending
2017.202	SYSTEMS AND METHODS FOR MULTI-ANALYSIS	Utility: Non-Provisional	13/769,820	2/18/2013	United States	Published
2017.203	SYSTEMS AND METHODS FOR FLUID AND COMPONENT HANDLING	Utility: Continuation	14/157,343	1/16/2014	United States	Pending
2017.204	SYSTEMS AND METHODS FOR MULTI-ANALYSIS	Utility: Non-Provisional	14/183,500	2/18/2014	United States	Pending
2017.205	SYSTEMS AND METHODS FOR MULTI-ANALYSIS	Utility: Non-Provisional	14/183,503	2/18/2014	United States	Pending
2017.602	SYSTEMS AND METHODS FOR MULTI-ANALYSIS	Utility: PCT	PCT/US14/16997	2/18/2014	World Intellectual Property Organization	Pending
2018.201	ANTIBODIES AND ANTIBODY FRAGMENTS THAT BIND FOLLICLE-STIMULATING HORMONE (FSH)	Utility: Non-Provisional	14/211,715	3/14/2014	United States	Pending
2018.601	ANTIBODIES AND ANTIBODY FRAGMENTS THAT SPECIFICALLY BIND FOLLICLE-STIMULATING HORMONE (FSH)	Utility: PCT	PCT/US14/29975	3/15/2014	World Intellectual Property Organization	Pending
2019.201	ANTIBODIES AND ANTIBODY FRAGMENTS THAT BIND THYROID STIMULATING HORMONE (TSH)	Utility: Non-Provisional	14/211,772	3/14/2014	United States	Pending
2020.201	ANTIBODIES AND ANTIBODY FRAGMENTS THAT BIND THYROXINE (T4)	Utility: Non-Provisional	14/211,823	3/14/2014	United States	Pending

theranos

Attorney Reference	Title	Type	Application Number	Filing Date	Country	Status
2020.601	ANTIBODIES AND ANTIBODY FRAGMENTS THAT SPECIFICALLY BIND THYROXINE (T4)	Utility: PCT	PCT/US14/29978	3/15/2014	World Intellectual Property Organization	Pending
2021.201	ANTIBODIES AND ANTIBODY FRAGMENTS THAT BIND EMETINE	Utility: Non-Provisional	14/211,880	3/14/2014	United States	Pending
2021.202	ANTIBODIES AND ANTIBODY FRAGMENTS THAT BIND EMETINE	Utility: Non-Provisional	14/211,912	3/14/2014	United States	Pending
2021.601	ANTIBODIES AND ANTIBODY FRAGMENTS THAT SPECIFICALLY BIND EMETINE	Utility: PCT	PCT/US14/29981	3/15/2014	World Intellectual Property Organization	Pending
2022.201	NETWORK CONNECTIVITY METHODS AND SYSTEMS	Utility: Continuation-in-Part	13/784,814	3/4/2013	United States	Published
2022.601	NETWORK CONNECTIVITY METHODS AND SYSTEMS	Utility: PCT	PCT/US14/20440	3/4/2014	World Intellectual Property Organization	Pending
2023.201	DEVICES, SYSTEMS AND METHODS FOR SAMPLE PREPARATION	Utility: Non-Provisional	14/203,436	3/10/2014	United States	Pending
2023.601	DEVICES, SYSTEMS AND METHODS FOR SAMPLE PREPARATION	Utility: PCT	PCT/US14/22847	3/10/2014	World Intellectual Property Organization	Pending
2024.102	METHODS AND DEVICES FOR SAMPLE COLLECTION AND SAMPLE SEPARATION	Utility: Provisional	61/948,542	3/5/2014	United States	Pending
2024.103	METHODS AND DEVICES FOR SAMPLE COLLECTION AND SAMPLE SEPARATION	Utility: Provisional	61/952,112	3/12/2014	United States	Pending
2024.201	METHODS AND DEVICES FOR SAMPLE COLLECTION AND SAMPLE SEPARATION	Utility: Non-Provisional	14/214,771	3/15/2014	United States	Pending

theranos

Attorney Reference	Title	Type	Application Number	Filing Date	Country	Status
2024.601	METHODS AND DEVICES FOR SAMPLE COLLECTION AND SAMPLE SEPARATION	Utility: PCT	PCT/US14/30070	3/15/2014	World Intellectual Property Organization	Pending
2025.201	Nucleic Acid Amplification	Utility: Non-Provisional	14/214,848	3/15/2014	United States	Pending
2025.601	NUCLEIC ACID AMPLIFICATION	Utility: PCT	PCT/US14/30028	3/15/2014	World Intellectual Property Organization	Pending
2026.102	Nucleic Acid Amplification	Utility: Provisional	61/908,027	11/22/2013	United States	Pending
2026.103	Nucleic Acid Amplification	Utility: Provisional	62/001,050	5/20/2014	United States	Pending
2026.201	Nucleic Acid Amplification	Utility: Non-Provisional	14/214,850	3/15/2014	United States	Pending
2026.601	Nucleic Acid Amplification	Utility: PCT	PCT/US14/30034	3/15/2014	World Intellectual Property Organization	Pending
2028.201	THERMOSTABLE BLUNT-END LIGASE AND METHODS OF USE	Utility: Non-Provisional	14/214,834	3/15/2014	United States	Pending
2028.601	THERMOSTABLE BLUNT-END LIGASE AND METHODS OF USE	Utility: PCT	PCT/US14/30003	3/15/2014	World Intellectual Property Organization	Pending
2029.204	MODULAR POINT-OF-CARE DEVICES, SYSTEMS, AND USES THEREOF	Utility: Non-Provisional	13/889,674	5/8/2013	United States	Allowed
2029.205	MODULAR POINT-OF-CARE DEVICES, SYSTEMS, AND USES THEREOF	Utility: Non-Provisional	13/893,258	5/13/2013	United States	Published
2029.206	MODULAR POINT-OF-CARE DEVICES, SYSTEMS, AND USES THEREOF	Utility: Non-Provisional	13/916,553	6/12/2013	United States	Issued

theranos

Attorney Reference	Title	Type	Application Number	Filing Date	Country	Status
2030.201	FEMTOWATT NON-VACUUM TUBE DETECTOR ASSEMBLY	Utility: Non-Provisional	14/214,602	3/14/2014	United States	Pending
2030.601	FEMTOWATT NON-VACUUM TUBE DETECTOR ASSEMBLY	Utility: PCT	PCT/US14/30823	3/17/2014	World Intellectual Property Organization	Pending
2031.201	Nucleic Acid Amplification	Utility: Non-Provisional	14/214,854	3/15/2014	United States	Pending
2031.601	NUCLEIC ACID AMPLIFICATION	Utility: PCT	PCT/US14/30036	3/15/2014	World Intellectual Property Organization	Pending
2032.201	SYSTEMS, DEVICES, AND METHODS FOR INTEGRATED PATIENT SERVICE CENTER	Utility: Non-Provisional	14/214,599	3/14/2014	United States	Pending
3000.102	METHODS FOR OBTAINING BLOOD FROM A SUBJECT	Utility: Provisional	61/874,893	9/6/2013	United States	Pending
3000.201	METHODS FOR OBTAINING BLOOD FROM A SUBJECT	Utility: Non-Provisional	14/220,013	3/19/2014	United States	Pending
3001.102	METHODS, DEVICES, AND SYSTEMS FOR SAMPLE ANALYSIS	Utility: Provisional	62/011,016	6/11/2014	United States	Pending
3001.601	METHODS, DEVICES, AND SYSTEMS FOR SAMPLE ANALYSIS	Utility: PCT	PCT/US14/32071	3/27/2014	World Intellectual Property Organization	Pending
3002.601	BIOLOGICAL SAMPLE PROCESSING	Utility: PCT	PCT/US14/32092	3/27/2014	World Intellectual Property Organization	Pending
3004.102	Methods, Devices and Systems for Secure Transport of Materials	Utility: Provisional	61/864,505	8/9/2013	United States	Pending
3004.201	Methods, Devices and Systems for Secure Transport of Materials	Utility: Non-Provisional	14/259,105	4/22/2014	United States	Pending

theranos

Attorney Reference	Title	Type	Application Number	Filing Date	Country	Status
3004.601	METHODS, DEVICES, AND SYSTEMS FOR SECURE TRANSPORT OF MATERIALS	Utility: PCT	PCT/US14/35050	4/22/2014	World Intellectual Property Organization	Pending
3005.101	Methods for Improving Assays of Biological Samples	Utility: Provisional	61/858,589	7/25/2013	United States	Pending
3005.102	METHODS FOR IMPROVING ASSAYS OF BIOLOGICAL SAMPLES	Utility: Provisional	61/903,346	11/12/2013	United States	Pending
3006.201	Antibodies and Antibody Fragments That Specifically Bind C-Reactive Protein	Utility: Non-Provisional	14/292,582	5/30/2014	United States	Pending
3007.201	Antibodies and Antibody Fragments that Specifically Bind Triiodothyronine (T3)	Utility: Non-Provisional	14/295,152	6/3/2014	United States	Pending
3008.201	Devices, Systems, and Methods for Cell Analysis in Microgravity	Utility: Non-Provisional	14/309,689	6/19/2014	United States	Pending
3009.201	METHODS AND DEVICES FOR SMALL VOLUME LIQUID CONTAINMENT	Utility: Non-Provisional	14/309,877	6/19/2014	United States	Pending
3010.201	METHODS AND DEVICES FOR SAMPLE ANALYSIS	Utility: Non-Provisional	14/309,888	6/19/2014	United States	Pending
3011.101	SYSTEMS AND METHODS FOR A DISTRIBUTED CLINICAL LABORATORY	Utility: Provisional	61/858,604	7/25/2013	United States	Pending
3012.101	SYSTEMS and METHODS for DETECTING INFECTIOUS DISEASES	Utility: Provisional	61/874,976	9/6/2013	United States	Pending
3012.102	SYSTEMS and METHODS for DETECTING INFECTIOUS DISEASES	Utility: Provisional	61/885,462	10/1/2013	United States	Pending
3012.103	Systems and Methods for Detecting Infectious Diseases	Utility: Provisional	62/001,039	5/20/2014	United States	Pending
3012.104	Systems and MEthods for Detecting infectious diseases	Utility: Provisional	62/001,053	5/21/2014	United States	Pending
3012.105	Systems and Methods for Detecting Infectious Diseases	Utility: Provisional	62/010,382	6/10/2014	United States	Pending
3013.101	DEVICES, METHODS AND SYSTEMS FOR REDUCING SAMPLE VOLUME	Utility: Provisional	61/875,678	9/9/2013	United States	Pending

theranos

Attorney Reference	Title	Type	Application Number	Filing Date	Country	Status
3013.102	Devices, Methods and Systems for Reducing Sample Volume	Utility: Provisional	61/888,318	10/8/2013	United States	Pending
3014.101	Methods, Devices, and Systems Having Multiple Passwords	Utility: Provisional	61/877,560	9/13/2013	United States	Pending
3015.101	SYSTEMS AND METHODS FOR APPOINTMENT SCHEDULING AND CHECK IN	Utility: Provisional	61/875,108	9/8/2013	United States	Pending
3015.102	SYSTEMS AND METHODS FOR APPOINTMENT SCHEDULING AND CHECK IN	Utility: Provisional	61/899,869	11/4/2013	United States	Pending
3015.103	SYSTEMS AND METHODS FOR APPOINTMENT SCHEDULING AND CHECK IN	Utility: Provisional	61/900,985	11/6/2013	United States	Pending
3015.104	SYSTEMS AND METHODS FOR APPOINTMENT SCHEDULING AND CHECK IN	Utility: Provisional	62/001,542	5/21/2014	United States	Pending
3016.101	SYSTEMS AND METHODS FOR LABORATORY TESTING AND RESULTS MANAGEMENT	Utility: Provisional	61/874,983	9/6/2013	United States	Pending
3016.102	SYSTEMS AND METHODS FOR LABORATORY TESTING AND RESULT MANAGEMENT	Utility: Provisional	62/010,421	6/10/2014	United States	Pending
3016.201	SYSTEMS AND METHODS FOR LABORATORY TESTING AND RESULT MANAGEMENT	Utility: Non-Provisional	14/020,785	9/6/2013	United States	Pending
3018.101	SYSTEMS, DEVICES, AND METHODS FOR BODILY FLUID SAMPLE TRANSPORT	Utility: Provisional	61/875,030	9/7/2013	United States	Pending
3019.101	Methods and Systems for Obtaining Clinical Samples	Utility: Provisional	61/875,092	9/8/2013	United States	Pending
3019.102	METHODS AND SYSTEMS FOR OBTAINING CLINICAL SAMPLES	Utility: Provisional	61/894,166	10/22/2013	United States	Pending
3020.101	Systems, devices, and methods for integrated patient service center	Utility: Provisional	61/959,958	9/6/2013	United States	Pending
3021.101	SYSTEMS AND METHODS FOR ANALYTE TESTING AND DATA MANAGEMENT	Utility: Provisional	61/875,033	9/7/2013	United States	Pending
3021.102	SYSTEMS AND METHODS FOR ANALYTE TESTING AND DATA MANAGEMENT	Utility: Provisional	61/875,687	9/9/2013	United States	Pending
3022.101	SYSTEMS, DEVICES, AND METHODS FOR BODILY FLUID SAMPLE TRANSPORT	Utility: Provisional	61/875,107	9/8/2013	United States	Pending

theranos

Attorney Reference	Title	Type	Application Number	Filing Date	Country	Status
3023.101	SYSTEMS AND METHODS FOR ANALYTE TESTING AND LABORATORY OVERSIGHT	Utility: Provisional	61/879,671	9/18/2013	United States	Pending
3023.102	SYSTEMS AND METHODS FOR ANALYTE TESTING AND LABORATORY OVERSIGHT	Utility: Provisional	61/879,667	9/18/2013	United States	Pending
3023.103	SYSTEMS AND METHODS FOR ANALYTE TESTING AND LABORATORY OVERSIGHT	Utility: Provisional	61/882,624	9/25/2013	United States	Pending
3023.104	SYSTEMS AND METHODS FOR SAMPLE HANDLING	Utility: Provisional	61/944,567	2/25/2014	United States	Pending
3024.101	DEVICES, SYSTEMS, METHODS, AND KITS FOR RECEIVING A SWAB	Utility: Provisional	61/879,664	9/18/2013	United States	Pending
3024.102	DEVICES, SYSTEMS, METHODS AND KITS FOR RECEIVING A SWAB	Utility: Provisional	61/885,467	10/1/2013	United States	Pending
3025.101	Methods and Systems for Obtaining Clinical Samples	Utility: Provisional	61/890,870	10/14/2013	United States	Pending
3026.101	SYSTEMS AND METHODS FOR ORDERING LABORATORY TESTS AND PROVIDING RESULTS THEREOF	Utility: Provisional	61/895,239	10/24/2013	United States	Pending
3027.101	METHODS AND SYSTEMS FOR A SAMPLE COLLECTION DEVICE WITH A NOVELTY EXTERIOR	Utility: Provisional	61/902,777	11/11/2013	United States	Pending
3028.101	Preventive Medicine and Optimizing Health	Utility: Provisional	62/004,134	5/28/2014	United States	Pending
3029.101	Methods for Analysis of Small Samples	Utility: Provisional	61/993,566	5/15/2014	United States	Pending
3030.101	UNIFIED DETECTION SYSTEM FOR FLUOROMETRY, LUMINOMETRY AND SPECTROMETRY	Utility: Provisional	61/930,357	1/22/2014	United States	Pending
3031.101	SYSTEMS, DEVICES, AND METHODS FOR SAMPLE INTEGRITY VERIFICATION	Utility: Provisional	61/944,557	2/25/2014	United States	Pending
3032.101	Nucleic Acid Amplification	Utility: Provisional	62/001,032	5/20/2014	United States	Pending
3032.102	Nucleic Acid Amplification	Utility: Provisional	62/001,042	5/20/2014	United States	Pending

theranos

Attorney Reference	Title	Type	Application Number	Filing Date	Country	Status
3033.101	Devices and Methods for use with a Sample Container	Utility: Provisional	62/011,572	6/13/2014	United States	Pending
30696-704.201	MEDICAL DEVICE FOR ANALYTE MONITORING AND DRUG DELIVERY	Utility: Non-Provisional	10/937,872	9/10/2004	United States	Issued
30696-704.301	MEDICAL DEVICE FOR ANALYTE MONITORING AND DRUG DELIVERY	Utility: Non-Provisional	13/049,813	3/16/2011	United States	Published
30696-704.401	MEDICAL DEVICE FOR ANALYTE MONITORING AND DRUG DELIVERY	Utility: Non-Provisional	11/202,206	8/12/2005	United States	Issued
30696-704.402	MEDICAL DEVICE FOR ANALYTE MONITORING AND DRUG DELIVERY	Utility: Non-Provisional	11/202,231	8/12/2005	United States	Issued
30696-704.611	MEDICAL DEVICE FOR ANALYTE MONITORING AND DRUG DELIVERY	Utility: Foreign	0 478 8658.5	9/10/2004	European Patent Office	Issued
30696-704.612	MEDICAL DEVICE FOR ANALYTE MONITORING AND DRUG DELIVERY	Utility: Divisional	10179887.4	9/10/2004	European Patent Office	Pending
30696-704.621	MEDICAL DEVICE FOR ANALYTE MONITORING AND DRUG DELIVERY	Utility: Foreign	0 478 8658.5	9/10/2004	Germany	Issued
30696-704.631	MEDICAL DEVICE FOR ANALYTE MONITORING AND DRUG DELIVERY	Utility: Foreign	0 478 8658.5	9/10/2004	France	Issued
30696-704.641	MEDICAL DEVICE FOR ANALYTE MONITORING AND DRUG DELIVERY	Utility: Foreign	0 478 8658.5	9/10/2004	United Kingdom	Issued
30696-704.650	MEDICAL DEVICE FOR ANALYTE MONITORING AND DRUG DELIVERY	Utility: Foreign	0 478 8658.5	9/10/2004	Austria	Issued
30696-704.651	MEDICAL DEVICE FOR ANALYTE MONITORING AND DRUG DELIVERY	Utility: Foreign	0 478 8658.5	9/10/2004	Belgium	Issued
30696-704.653	MEDICAL DEVICE FOR ANALYTE MONITORING AND DRUG DELIVERY	Utility: Foreign	0 478 8658.5	9/10/2004	Switzerland	Issued
30696-704.654	MEDICAL DEVICE FOR ANALYTE MONITORING AND DRUG DELIVERY	Utility: Foreign	0 478 8658.5	9/10/2004	Cyprus	Issued
30696-704.656	MEDICAL DEVICE FOR ANALYTE MONITORING AND DRUG DELIVERY	Utility: Foreign	0 478 8658.5	9/10/2004	Denmark	Issued
30696-704.658	MEDICAL DEVICE FOR ANALYTE MONITORING AND DRUG DELIVERY	Utility: Foreign	0 478 8658.5	9/10/2004	Spain	Issued

theranos

Attorney Reference	Title	Type	Application Number	Filing Date	Country	Status
30696-704.659	MEDICAL DEVICE FOR ANALYTE MONITORING AND DRUG DELIVERY	Utility: Foreign	0 478 8658.5	9/10/2004	Finland	Issued
30696-704.660	MEDICAL DEVICE FOR ANALYTE MONITORING AND DRUG DELIVERY	Utility: Foreign	0 478 8658.5	9/10/2004	Greece	Issued
30696-704.661	MEDICAL DEVICE FOR ANALYTE MONITORING AND DRUG DELIVERY	Utility: Foreign	0 478 8658.5	9/10/2004	Hungary	Issued
30696-704.662	MEDICAL DEVICE FOR ANALYTE MONITORING AND DRUG DELIVERY	Utility: Foreign	0 478 8658.5	9/10/2004	Ireland	Issued
30696-704.663	MEDICAL DEVICE FOR ANALYTE MONITORING AND DRUG DELIVERY	Utility: Foreign	0 478 8658.5	9/10/2004	Italy	Issued
30696-704.664	MEDICAL DEVICE FOR ANALYTE MONITORING AND DRUG DELIVERY	Utility: Foreign	0 478 8658.5	9/10/2004	Luxembourg	Issued
30696-704.665	MEDICAL DEVICE FOR ANALYTE MONITORING AND DRUG DELIVERY	Utility: Foreign	0 478 8658.5	9/10/2004	Monaco	Issued
30696-704.666	MEDICAL DEVICE FOR ANALYTE MONITORING AND DRUG DELIVERY	Utility: Foreign	0 478 8658.5	9/10/2004	Netherlands	Issued
30696-704.667	MEDICAL DEVICE FOR ANALYTE MONITORING AND DRUG DELIVERY	Utility: Foreign	0 478 8658.5	9/10/2004	Portugal	Issued
30696-704.669	MEDICAL DEVICE FOR ANALYTE MONITORING AND DRUG DELIVERY	Utility: Foreign	0 478 8658.5	9/10/2004	Sweden	Issued
30696-704.672	MEDICAL DEVICE FOR ANALYTE MONITORING AND DRUG DELIVERY	Utility: Foreign	0 478 8658.5	9/10/2004	Turkey	Issued
30696-704.681	MEDICAL DEVICE FOR ANALYTE MONITORING AND DRUG DELIVERY	Utility: Foreign	2004272062	9/10/2004	Australia	Issued
30696-704.682	MEDICAL DEVICE FOR ANALYTE MONITORING AND DRUG DELIVERY	Utility: Foreign	2010241506	9/10/2004	Australia	Issued
30696-704.683	MEDICAL DEVICE FOR ANALYTE MONITORING AND DRUG DELIVERY	Utility: Divisional	2012213965	9/10/2004	Australia	Pending
30696-704.701	MEDICAL DEVICE FOR ANALYTE MONITORING AND DRUG DELIVERY	Utility: Foreign	2,538,038	9/10/2004	Canada	Pending

theranos

Attorney Reference	Title	Type	Application Number	Filing Date	Country	Status
30696-704.702	MEDICAL DEVICE FOR ANALYTE MONITORING AND DRUG DELIVERY	Utility: Foreign Divisional	2,852,974	5/30/2014	Canada	Pending
30696-704.711	MEDICAL DEVICE FOR ANALYTE MONITORING AND DRUG DELIVERY	Utility: Foreign	CN 0480030548.5	9/10/2004	China	Issued
30696-704.731	MEDICAL DEVICE FOR ANALYTE MONITORING AND DRUG DELIVERY	Utility: Foreign	174103	9/10/2004	Israel	Issued
30696-704.741	MEDICAL DEVICE FOR ANALYTE MONITORING AND DRUG DELIVERY	Utility: Foreign	1291/DELNP/06	9/10/2004	India	Issued
30696-704.742	MEDICAL DEVICE FOR ANALYTE MONITORING AND DRUG DELIVERY	Utility: Divisional	7135/DELNP/09	9/10/2004	India	Pending
30696-704.761	MEDICAL DEVICE FOR ANALYTE MONITORING AND DRUG DELIVERY	Utility: Foreign	2006-526288	9/10/2004	Japan	Issued
30696-704.762	MEDICAL DEVICE FOR ANALYTE MONITORING AND DRUG DELIVERY	Utility: Foreign Divisional	2010-96515	9/10/2004	Japan	Issued
30696-704.763	MEDICAL DEVICE FOR ANALYTE MONITORING AND DRUG DELIVERY	Utility: Divisional	2012-179402	9/10/2004	Japan	Published
30696-704.764	MEDICAL DEVICE FOR ANALYTE MONITORING AND DRUG DELIVERY	Utility: Divisional	2014-092245	4/28/2014	Japan	Pending
30696-704.771	MEDICAL DEVICE FOR ANALYTE MONITORING AND DRUG DELIVERY	Utility: Foreign	10-06-7006816	9/10/2004	Republic of Korea	Issued
30696-704.772	MEDICAL DEVICE FOR ANALYTE MONITORING AND DRUG DELIVERY	Utility: Foreign	10-2012-7008407	9/10/2004	Republic of Korea	Issued
30696-704.773	MEDICAL DEVICE FOR ANALYTE MONITORING AND DRUG DELIVERY	Utility: Divisional	10-2012-7022103	9/10/2004	Republic of Korea	Pending
30696-704.774	MEDICAL DEVICE FOR ANALYTE MONITORING AND DRUG DELIVERY	Utility: Divisional	10-2012-7032495	9/10/2004	Republic of Korea	Pending
30696-704.775	MEDICAL DEVICE FOR ANALYTE MONITORING AND DRUG DELIVERY	Utility: Divisional	10-2013-7032653	12/9/2013	Republic of Korea	Pending
30696-704.791	MEDICAL DEVICE FOR ANALYTE MONITORING AND DRUG DELIVERY	Utility: Foreign	546432	9/10/2004	New Zealand	Issued

theranos

Attorney Reference	Title	Type	Application Number	Filing Date	Country	Status
30696-704.792	MEDICAL DEVICE FOR ANALYTE MONITORING AND DRUG DELIVERY	Utility: Foreign	580449	9/10/2004	New Zealand	Issued
30696-704.891	MEDICAL DEVICE FOR ANALYTE MONITORING AND DRUG DELIVERY	Utility: Foreign	HK 11110543.8	9/10/2004	Hong Kong	Pending
30696-704.941	MEDICAL DEVICE FOR ANALYTE MONITORING AND DRUG DELIVERY	Utility: Foreign	0 478 8658.5	9/10/2004	Poland	Issued
30696-707.201	POINT-OF-CARE FLUIDIC SYSTEMS AND USES THEREOF	Utility: Non-Provisional	11/389,409	3/24/2006	United States	Issued
30696-707.301	POINT-OF-CARE FLUIDIC SYSTEMS AND USES THEREOF	Utility: Non-Provisional	12/576,197	10/8/2009	United States	Issued
30696-707.305	POINT-OF-CARE FLUIDIC SYSTEMS AND USES THEREOF	Utility: Continuation	13/647,325	10/8/2012	United States	Published
30696-707.306	Systems and Methods for Analying Bodily Fluids	Utility: Continuation	13/896,171	5/16/2013	United States	Pending
30696-707.611	POINT-OF-CARE FLUIDIC SYSTEMS AND USES THEREOF	Utility: Foreign	6748733	3/24/2006	European Patent Office	Published
30696-707.681	POINT-OF-CARE FLUIDIC SYSTEMS AND USES THEREOF	Utility: Foreign	2006244617	3/24/2006	Australia	Issued
30696-707.682	POINT-OF-CARE FLUIDIC SYSTEMS AND USES THEREOF	Utility: Divisional	2013201509	3/24/2006	Australia	Pending
30696-707.701	POINT-OF-CARE FLUIDIC SYSTEMS AND USES THEREOF	Utility: Foreign	2610294	3/24/2006	Canada	Pending
30696-707.711	POINT-OF-CARE FLUIDIC SYSTEMS AND USES THEREOF	Utility: Foreign	200680024658.X	3/24/2006	China	Published
30696-707.731	POINT-OF-CARE FLUIDIC SYSTEMS AND USES THEREOF	Utility: Foreign	187272	3/24/2006	Israel	Pending
30696-707.732	POINT-OF-CARE FLUIDIC SYSTEMS AND USES THEREOF	Utility: Divisional	232544	5/11/2014	Israel	Pending
30696-707.741	POINT-OF-CARE FLUIDIC SYSTEMS AND USES THEREOF	Utility: Foreign	9452/DELNP/07	3/24/2006	India	Published
30696-707.761	POINT-OF-CARE FLUIDIC SYSTEMS AND USES THEREOF	Utility: Foreign	2008-511111	3/24/2006	Japan	Published

theranos

Attorney Reference	Title	Type	Application Number	Filing Date	Country	Status
30696-707.762	POINT-OF-CARE FLUIDIC SYSTEMS AND USES THEREOF	Utility: Divisional	2012-81306	3/24/2006	Japan	Pending
30696-707.763	POINT-OF-CARE FLUIDIC SYSTEMS AND USES THEREOF	Utility: Divisional	2012-238759	3/24/2006	Japan	Pending
30696-707.771	POINT-OF-CARE FLUIDIC SYSTEMS AND USES THEREOF	Utility: Foreign	2007-7028881	3/24/2006	Republic of Korea	Allowed
30696-707.772	POINT-OF-CARE FLUIDIC SYSTEMS AND USES THEREOF	Utility: Divisional	10-2011-7006832	12/10/2007	Republic of Korea	Pending
30696-707.773	POINT-OF-CARE FLUIDIC SYSTEMS AND USES THEREOF	Utility: Foreign	10-2013-7005225	3/24/2006	Republic of Korea	Allowed
30696-707.7731	POINT-OF-CARE FLUIDIC SYSTEMS AND USES THEREOF	Utility: Divisional	10-2013-7027526	3/24/2006	Republic of Korea	Pending
30696-707.781	POINT-OF-CARE FLUIDIC SYSTEMS AND USES THEREOF	Utility: Foreign	a/2007/013985	3/24/2006	Mexico	Issued
30696-707.782	POINT-OF-CARE FLUIDIC SYSTEMS AND USES THEREOF	Utility: Divisional	a/2013/001275	3/24/2006	Mexico	Allowed
30696-707.783	POINT-OF-CARE FLUIDIC SYSTEMS AND USES THEREOF	Utility: Non-Provisional	a/2013/001320	3/24/2006	Mexico	Pending
30696-707.791	POINT-OF-CARE FLUIDIC SYSTEMS AND USES THEREOF	Utility: Foreign	564141	3/24/2006	New Zealand	Issued
30696-707.792	POINT-OF-CARE FLUIDIC SYSTEMS AND USES THEREOF	Utility: Foreign	590930	3/24/2006	New Zealand	Issued
30696-707.793	POINT-OF-CARE FLUIDIC SYSTEMS AND USES THEREOF	Utility: Foreign	599522	3/24/2006	New Zealand	Issued
30696-707.794	POINT-OF-CARE FLUIDIC SYSTEMS AND USES THEREOF	Utility: Foreign	603604	3/24/2006	New Zealand	Issued
30696-707.795	POINT-OF-CARE FLUIDIC SYSTEMS AND USES THEREOF	Utility: Foreign	603613	3/24/2006	New Zealand	Issued
30696-707.796	POINT-OF-CARE FLUIDIC SYSTEMS AND USES THEREOF	Utility: Divisional	620811	3/24/2006	New Zealand	Pending
30696-707.891	POINT-OF-CARE FLUIDIC SYSTEMS AND USES THEREOF	Utility: Foreign	10102788	3/24/2006	Hong Kong	Published

theranos

Attorney Reference	Title	Type	Application Number	Filing Date	Country	Status
30696-709.201	Systems and methods for improving medical treatments	Utility: Non-Provisional	11/388,415	3/24/2006	United States	Issued
30696-709.401	Systems and methods for improving medical treatments	Utility: Divisional	14/080,727	11/14/2013	United States	Pending
30696-710.201	Systems and methods for conducting animal studies	Utility: Non-Provisional	11/388,823	3/24/2006	United States	Allowed
30696-711.201	CALIBRATION OF FLUIDIC DEVICES	Utility: Non-Provisional	11/388,824	3/24/2006	United States	Issued
30696-711.301	CALIBRATION OF FLUIDIC DEVICES	Utility: Non-Provisional	12/986,954	1/7/2011	United States	Published
30696-712.301	Fluidic Medical Devices and Uses Thereof	Utility: Non-Provisional	12/625,430	11/24/2009	United States	Published
30696-713.201	REAL-TIME DETECTION OF INFLUENZA VIRUS	Utility: Non-Provisional	11/746,535	5/9/2007	United States	Issued
30696-713.301	Real-Time Detection of Influenza Virus	Utility: Non-Provisional	13/187,960	7/21/2011	United States	Issued
30696-713.611	REAL-TIME DETECTION OF INFLUENZA VIRUS	Utility: Foreign	7762092	5/10/2007	European Patent Office	Issued
30696-713.612	REAL-TIME DETECTION OF INFLUENZA VIRUS	Utility: Foreign	11180769.6	5/10/2007	European Patent Office	Issued
30696-713.613	REAL-TIME DETECTION OF INFLUENZA VIRUS	Utility: Foreign Divisional	14 174846.7	6/27/2014	European Patent Office	Pending
30696-713.621	REAL-TIME DETECTION OF INFLUENZA VIRUS	Utility: Foreign	7762092	5/10/2007	Germany	Issued
30696-713.631	REAL-TIME DETECTION OF INFLUENZA VIRUS	Utility: Foreign	7762092	5/10/2007	France	Issued
30696-713.641	REAL-TIME DETECTION OF INFLUENZA VIRUS	Utility: Foreign	7762092	5/10/2007	United Kingdom	Issued
30696-713.651	REAL-TIME DETECTION OF INFLUENZA VIRUS	Utility: Foreign	7762092	5/10/2007	Belgium	Issued

theranos

Attorney Reference	Title	Type	Application Number	Filing Date	Country	Status
30696-713.653	REAL-TIME DETECTION OF INFLUENZA VIRUS	Utility: Foreign	7762092	5/10/2007	Switzerland	Issued
30696-713.656	REAL-TIME DETECTION OF INFLUENZA VIRUS	Utility: Foreign	7762092	5/10/2007	Denmark	Issued
30696-713.658	REAL-TIME DETECTION OF INFLUENZA VIRUS	Utility: Foreign	7762092	5/10/2007	Spain	Issued
30696-713.662	REAL-TIME DETECTION OF INFLUENZA VIRUS	Utility: Foreign	7762092	5/10/2007	Ireland	Issued
30696-713.663	REAL-TIME DETECTION OF INFLUENZA VIRUS	Utility: Foreign	7762092	5/10/2007	Italy	Issued
30696-713.664	REAL-TIME DETECTION OF INFLUENZA VIRUS	Utility: Foreign	7762092	5/10/2007	Luxembourg	Issued
30696-713.666	REAL-TIME DETECTION OF INFLUENZA VIRUS	Utility: Foreign	7762092	5/10/2007	Netherlands	Issued
30696-713.669	REAL-TIME DETECTION OF INFLUENZA VIRUS	Utility: Foreign	7762092	5/10/2007	Sweden	Issued
30696-713.672	REAL-TIME DETECTION OF INFLUENZA VIRUS	Utility: Foreign	7762092	5/10/2007	Turkey	Issued
30696-713.681	REAL-TIME DETECTION OF INFLUENZA VIRUS	Utility: Foreign	2007249334	5/10/2007	Australia	Issued
30696-713.682	REAL-TIME DETECTION OF INFLUENZA VIRUS	Utility: Divisional	2013270537	12/12/2013	Australia	Pending
30696-713.701	REAL-TIME DETECTION OF INFLUENZA VIRUS	Utility: Foreign	2650455	5/10/2007	Canada	Pending
30696-713.711	REAL-TIME DETECTION OF INFLUENZA VIRUS	Utility: Foreign	780016504	5/10/2007	China	Issued
30696-713.712	REAL-TIME DETECTION OF INFLUENZA VIRUS	Utility: Foreign	2.01E+11	5/10/2007	China	Published
30696-713.712-HK	REAL-TIME DETECTION OF INFLUENZA VIRUS	Utility: Foreign	13114296.7	12/26/2013	Hong Kong	Published

theranos

Attorney Reference	Title	Type	Application Number	Filing Date	Country	Status
30696-713.731	REAL-TIME DETECTION OF INFLUENZA VIRUS	Utility: Foreign	195108	5/10/2007	Israel	Issued
30696-713.741	REAL-TIME DETECTION OF INFLUENZA VIRUS	Utility: Foreign	9081/DELNP/08	5/10/2007	India	Published
30696-713.761	REAL-TIME DETECTION OF INFLUENZA VIRUS	Utility: Foreign	2009-510174	5/10/2007	Japan	Issued
30696-713.762	REAL-TIME DETECTION OF INFLUENZA VIRUS	Utility: Foreign	2011-237908	5/10/2007	Japan	Allowed
30696-713.763	REAL-TIME DETECTION OF INFLUENZA VIRUS	Utility: Divisional	2013-247236	5/10/2007	Japan	Published
30696-713.771	REAL-TIME DETECTION OF INFLUENZA VIRUS	Utility: Foreign	2008-7028354	5/10/2007	Republic of Korea	Allowed
30696-713.772	REAL-TIME DETECTION OF INFLUENZA VIRUS	Utility: Divisional	10-2013-7033688	12/18/2013	Republic of Korea	Pending
30696-713.773	REAL-TIME DETECTION OF INFLUENZA VIRUS	Utility: Foreign Divisional	10-2014-7017496	6/25/2014	Republic of Korea	Pending
30696-713.781	REAL-TIME DETECTION OF INFLUENZA VIRUS	Utility: Foreign	a/2008/014224	5/10/2007	Mexico	Issued
30696-713.782	REAL-TIME DETECTION OF INFLUENZA VIRUS	Utility: Divisional	MX/a/2012/003367	5/10/2007	Mexico	Allowed
30696-713.783	REAL-TIME DETECTION OF INFLUENZA VIRUS	Utility: Continuation	MX/a/2014/008154	7/2/2014	Mexico	Pending
30696-713.791	REAL-TIME DETECTION OF INFLUENZA VIRUS	Utility: Foreign	572480	5/10/2007	New Zealand	Issued
30696-713.891	REAL-TIME DETECTION OF INFLUENZA VIRUS	Utility: Foreign	9104140.2	5/10/2007	Hong Kong	Issued
30696-713.892	REAL-TIME DETECTION OF INFLUENZA VIRUS	Utility: Foreign	12109767.8	5/10/2007	Hong Kong	Published
30696-715.201	REDUCING OPTICAL INTERFERENCE IN A FLUIDIC DEVICE	Utility: Non-Provisional	11/549,558	10/13/2006	United States	Issued

theranos

Attorney Reference	Title	Type	Application Number	Filing Date	Country	Status
30696-715.301	REDUCING OPTICAL INTERFERENCE IN A FLUIDIC DEVICE	Utility: Non-Provisional	11/685,615	3/13/2007	United States	Issued
30696-715.302	REDUCING OPTICAL INTERFERENCE IN A FLUIDIC DEVICE	Utility: Non-Provisional	13/188,288	7/21/2011	United States	Issued
30696-715.303	REDUCING OPTICAL INTERFERENCE IN A FLUIDIC DEVICE	Utility: Continuation	13/915,362	6/11/2013	United States	Published
30696-715.611	REDUCING OPTICAL INTERFERENCE IN A FLUIDIC DEVICE	Utility: Foreign	7868405.7	10/10/2007	European Patent Office	Published
30696-715.612	REDUCING OPTICAL INTERFERENCE IN A FLUIDIC DEVICE	Utility: Divisional	13161756.5	10/10/2007	European Patent Office	Published
30696-715.681	REDUCING OPTICAL INTERFERENCE IN A FLUIDIC DEVICE	Utility: Foreign	2007324129	10/10/2007	Australia	Issued
30696-715.682	REDUCING OPTICAL INTERFERENCE IN A FLUIDIC DEVICE	Utility: Divisional	2013267006	12/4/2013	Australia	Pending
30696-715.701	REDUCING OPTICAL INTERFERENCE IN A FLUIDIC DEVICE	Utility: Foreign	2666338	10/10/2007	Canada	Pending
30696-715.711	REDUCING OPTICAL INTERFERENCE IN A FLUIDIC DEVICE	Utility: Foreign	2.01E+11	10/10/2007	China	Published
30696-715.731	REDUCING OPTICAL INTERFERENCE IN A FLUIDIC DEVICE	Utility: Foreign	198113	10/10/2007	Israel	Allowed
30696-715.7311	REDUCING OPTICAL INTERFERENCE IN A FLUIDIC DEVICE	Utility: Divisional	227945	10/10/2007	Israel	Allowed
30696-715.741	REDUCING OPTICAL INTERFERENCE IN A FLUIDIC DEVICE	Utility: Foreign	2233/DELNP/09	10/10/2007	India	Published
30696-715.761	REDUCING OPTICAL INTERFERENCE IN A FLUIDIC DEVICE	Utility: Foreign	2009-532550	10/10/2007	Japan	Issued
30696-715.762	REDUCING OPTICAL INTERFERENCE IN A FLUIDIC DEVICE	Utility: Foreign	2013-37058	10/10/2007	Japan	Pending
30696-715.763	REDUCING OPTICAL INTERFERENCE IN A FLUIDIC DEVICE	Utility: Foreign Divisional	2014-121153	6/12/2014	Japan	Pending

theranos

Attorney Reference	Title	Type	Application Number	Filing Date	Country	Status
30696-715.771	REDUCING OPTICAL INTERFERENCE IN A FLUIDIC DEVICE	Utility: Foreign	2009-7009660	10/10/2007	Republic of Korea	Pending
30696-715.772	REDUCING OPTICAL INTERFERENCE IN A FLUIDIC DEVICE	Utility: Divisional	10-2014-7007309	3/19/2014	Republic of Korea	Pending
30696-715.781	REDUCING OPTICAL INTERFERENCE IN A FLUIDIC DEVICE	Utility: Foreign	a/2009/003572	10/10/2007	Mexico	Issued
30696-715.782	REDUCING OPTICAL INTERFERENCE IN A FLUIDIC DEVICE	Utility: Foreign	a/2012/009292	10/10/2007	Mexico	Pending
30696-715.791	REDUCING OPTICAL INTERFERENCE IN A FLUIDIC DEVICE	Utility: Foreign	576116	10/10/2007	New Zealand	Issued
30696-715.792	REDUCING OPTICAL INTERFERENCE IN A FLUIDIC DEVICE	Utility: Foreign	600177	10/10/2007	New Zealand	Issued
30696-715.7921	REDUCING OPTICAL INTERFERENCE IN A FLUIDIC DEVICE	Utility: Divisional	616116	10/10/2007	New Zealand	Pending
30696-715.891	REDUCING OPTICAL INTERFERENCE IN A FLUIDIC DEVICE	Utility: Foreign	9111657.2	10/10/2007	Hong Kong	Published
30696-720.301	DETECTION AND QUANTIFICATION OF ANALYTES IN BODILY FLUIDS	Utility: Continuation	12/750,518	3/30/2010	United States	Issued
30696-722.501	Systems and Methods of Sample Processing and Fluid Control in a Fluidic System	Utility: Non-Provisional	11/554,509	10/30/2006	United States	Issued
30696-725.301	METHODS AND SYSTEMS FOR ASSESSING CLINICAL OUTCOMES	Utility: Non-Provisional	13/609,144	9/10/2012	United States	Issued
30696-725.302	METHODS AND SYSTEMS FOR ASSESSING CLINICAL OUTCOMES	Utility: Continuation	14/011,730	8/27/2013	United States	Published
30696-725.401	METHODS AND SYSTEMS FOR ASSESSING CLINICAL OUTCOMES	Utility: Non-Provisional	13/244,762	9/26/2011	United States	Issued
30696-725.611	METHODS AND SYSTEMS FOR ASSESSING CLINICAL OUTCOMES	Utility: Foreign	09 723974.3	3/26/2009	European Patent Office	Published
30696-725.681	METHODS AND SYSTEMS FOR ASSESSING CLINICAL OUTCOMES	Utility: Foreign	2009228145	3/26/2009	Australia	Issued
30696-725.6811	METHODS AND SYSTEMS FOR ASSESSING CLINICAL OUTCOMES	Utility: Divisional	2013231105	3/26/2009	Australia	Pending

theranos

Attorney Reference	Title	Type	Application Number	Filing Date	Country	Status
30696-725.691	METHODS AND SYSTEMS FOR ASSESSING CLINICAL OUTCOMES	Utility: Foreign	PI 0910608-1	3/26/2009	Brazil	Pending
30696-725.701	METHODS AND SYSTEMS FOR ASSESSING CLINICAL OUTCOMES	Utility: Foreign	2,719,625	3/26/2009	Canada	Pending
30696-725.711	METHODS AND SYSTEMS FOR ASSESSING CLINICAL OUTCOMES	Utility: Foreign	2.01E+11	3/26/2009	China	Published
30696-725.731	METHODS AND SYSTEMS FOR ASSESSING CLINICAL OUTCOMES	Utility: Foreign	208323	3/26/2009	Israel	Pending
30696-725.741	METHODS AND SYSTEMS FOR ASSESSING CLINICAL OUTCOMES	Utility: Foreign	6605/CHENP/10	3/26/2009	India	Published
30696-725.761	METHODS AND SYSTEMS FOR ASSESSING CLINICAL OUTCOMES	Utility: Foreign	2011-502079	3/26/2009	Japan	Issued
30696-725.762	METHODS AND SYSTEMS FOR ASSESSING CLINICAL OUTCOMES	Utility: Divisional	2014-38435	2/28/2014	Japan	Pending
30696-725.771	METHODS AND SYSTEMS FOR ASSESSING CLINICAL OUTCOMES	Utility: Foreign	2010-7023945	3/26/2009	Republic of Korea	Pending
30696-725.781	METHODS AND SYSTEMS FOR ASSESSING CLINICAL OUTCOMES	Utility: Foreign	a/2010/010400	3/26/2009	Mexico	Pending
30696-725.782	METHODS AND SYSTEMS FOR ASSESSING CLINICAL OUTCOMES	Utility: Divisional	MX/a/2014/000377	1/9/2014	Mexico	Pending
30696-725.791	METHODS AND SYSTEMS FOR ASSESSING CLINICAL OUTCOMES	Utility: Foreign	588741	3/26/2009	New Zealand	Allowed
30696-725.7911	METHODS AND SYSTEMS FOR ASSESSING CLINICAL OUTCOMES	Utility: Divisional	614566	3/26/2009	New Zealand	Pending
30696-725.811	METHODS AND SYSTEMS FOR ASSESSING CLINICAL OUTCOMES	Utility: Foreign	2010143465	3/26/2009	Russian Federation	Pending
30696-725.821	METHODS AND SYSTEMS FOR ASSESSING CLINICAL OUTCOMES	Utility: Foreign	2010006966-4	3/26/2009	Singapore	Issued
30696-725.822	METHODS AND SYSTEMS FOR ASSESSING CLINICAL OUTCOMES	Utility: Divisional	201109703-7	3/26/2009	Singapore	Pending
30696-725.823	METHODS AND SYSTEMS FOR ASSESSING CLINICAL OUTCOMES	Utility: Divisional	201109708-6	3/26/2009	Singapore	Pending

theranos

Attorney Reference	Title	Type	Application Number	Filing Date	Country	Status
30696-725.824	METHODS AND SYSTEMS FOR ASSESSING CLINICAL OUTCOMES	Utility: Divisional	201109710-2	3/26/2009	Singapore	Pending
30696-725.891	METHODS AND SYSTEMS FOR ASSESSING CLINICAL OUTCOMES	Utility: Foreign	11111057.4	3/26/2009	Hong Kong	Pending
30696-726.201	SYSTEMS AND METHODS OF FLUIDIC SAMPLE PROCESSING	Utility: Non-Provisional	12/221,816	8/6/2008	United States	Issued
30696-726.301	SYSTEMS AND METHODS OF FLUIDIC SAMPLE PROCESSING	Utility: Non-Provisional	13/436,568	3/30/2012	United States	Published
30696-727.201	MODULAR POINT-OF-CARE DEVICES, SYSTEMS, AND USES THEREOF	Utility: Non-Provisional	12/244,723	10/2/2008	United States	Issued
30696-727.301	MODULAR POINT-OF-CARE DEVICES, SYSTEMS, AND USES THEREOF	Utility: Non-Provisional	13/326,023	12/14/2011	United States	Published
30696-727.611	MODULAR POINT-OF-CARE DEVICES, AND USES THEREOF	Utility: Foreign	8836072.2	10/2/2008	European Patent Office	Issued
30696-727.612	MODULAR POINT-OF-CARE DEVICES, AND USES THEREOF	Utility: Foreign Divisional	13178059.5	10/2/2008	European Patent Office	Published
30696-727.621	MODULAR POINT-OF-CARE DEVICES, AND USES THEREOF	Utility: Foreign		10/2/2008	Germany	Issued
30696-727.631	MODULAR POINT-OF-CARE DEVICES, AND USES THEREOF	Utility: Foreign		10/2/2008	France	Issued
30696-727.641	MODULAR POINT-OF-CARE DEVICES, AND USES THEREOF	Utility: Foreign		10/2/2008	United Kingdom	Issued
30696-727.653	MODULAR POINT-OF-CARE DEVICES, AND USES THEREOF	Utility: Foreign		10/2/2008	Switzerland	Issued
30696-727.656	MODULAR POINT-OF-CARE DEVICES, AND USES THEREOF	Utility: Foreign		10/2/2008	Denmark	Issued
30696-727.658	MODULAR POINT-OF-CARE DEVICES, AND USES THEREOF	Utility: Foreign		10/2/2008	Spain	Issued
30696-727.662	MODULAR POINT-OF-CARE DEVICES, AND USES THEREOF	Utility: Foreign		10/2/2008	Ireland	Issued

theranos

Attorney Reference	Title	Type	Application Number	Filing Date	Country	Status
30696-727.663	MODULAR POINT-OF-CARE DEVICES, AND USES THEREOF	Utility: Foreign		10/2/2008	Italy	Issued
30696-727.666	MODULAR POINT-OF-CARE DEVICES, AND USES THEREOF	Utility: Foreign		10/2/2008	Netherlands	Issued
30696-727.669	MODULAR POINT-OF-CARE DEVICES, AND USES THEREOF	Utility: Foreign		10/2/2008	Sweden	Issued
30696-727.681	MODULAR POINT-OF-CARE DEVICES, AND USES THEREOF	Utility: Foreign	2008308686	10/2/2008	Australia	Pending
30696-727.682	MODULAR POINT-OF-CARE DEVICES, AND USES THEREOF	Utility: Foreign Divisional	2013205047	10/2/2008	Australia	Pending
30696-727.683	MODULAR POINT-OF-CARE DEVICES, AND USES THEREOF	Utility: Foreign Divisional	2013205052	10/2/2008	Australia	Pending
30696-727.691	MODULAR POINT-OF-CARE DEVICES, AND USES THEREOF	Utility: Foreign	PI 0820328-8	10/2/2008	Brazil	Pending
30696-727.701	INTEGRATED HEALTH DATA CAPTURE AND ANALYSIS SYSTEM	Utility: Foreign	2701794	10/2/2008	Canada	Allowed
30696-727.711	MODULAR POINT-OF-CARE DEVICES, AND USES THEREOF	Utility: Foreign	880118646.2	10/2/2008	China	Allowed
30696-727.712	MODULAR POINT-OF-CARE DEVICES, AND USES THEREOF	Utility: Foreign Divisional	201310170188.X	10/2/2008	China	Pending
30696-727.731	MODULAR POINT-OF-CARE DEVICES, AND USES THEREOF	Utility: Foreign	204877	10/2/2008	Israel	Allowed
30696-727.7311	MODULAR POINT-OF-CARE DEVICES, AND USES THEREOF	Utility: Foreign Divisional	223603	10/2/2008	Israel	Pending
30696-727.7312	MODULAR POINT-OF-CARE DEVICES, AND USES THEREOF	Utility: Foreign Divisional	223604	10/2/2008	Israel	Pending

theranos

Attorney Reference	Title	Type	Application Number	Filing Date	Country	Status
30696-727.732	MODULAR POINT-OF-CARE DEVICES, AND USES THEREOF	Utility: Foreign Divisional	223599	10/2/2008	Israel	Pending
30696-727.733	MODULAR POINT-OF-CARE DEVICES, AND USES THEREOF	Utility: Foreign Divisional	223600	10/2/2008	Israel	Pending
30696-727.734	MODULAR POINT-OF-CARE DEVICES, AND USES THEREOF	Utility: Foreign Divisional	223601	10/2/2008	Israel	Pending
30696-727.735	MODULAR POINT-OF-CARE DEVICES, AND USES THEREOF	Utility: Foreign Divisional	223602	10/2/2008	Israel	Pending
30696-727.741	MODULAR POINT-OF-CARE DEVICES, AND USES THEREOF	Utility: Foreign	3055/DELNP/10	10/2/2008	India	Pending
30696-727.761	MODULAR POINT-OF-CARE DEVICES, AND USES THEREOF	Utility: Foreign	2010-528139	10/2/2008	Japan	Issued
30696-727.762	MODULAR POINT-OF-CARE DEVICES, AND USES THEREOF	Utility: Foreign Divisional	2013-88250	10/2/2008	Japan	Pending
30696-727.763	MODULAR POINT-OF-CARE DEVICES, AND USES THEREOF	Utility: Foreign Divisional	2014-138289	7/4/2014	Japan	Pending
30696-727.771	MODULAR POINT-OF-CARE DEVICES, AND USES THEREOF	Utility: Foreign	2010-7009627	10/2/2008	Republic of Korea	Pending
30696-727.7711	MODULAR POINT-OF-CARE DEVICES, AND USES THEREOF	Utility: Foreign Divisional	10-2013-7025985	10/2/2008	Republic of Korea	Pending
30696-727.781	MODULAR POINT-OF-CARE DEVICES, AND USES THEREOF	Utility: Foreign	a/2010/003578	10/2/2008	Mexico	Issued
30696-727.782	MODULAR POINT-OF-CARE DEVICES, AND USES THEREOF	Utility: Foreign	a/2012/004302	10/2/2008	Mexico	Issued

theranos

Attorney Reference	Title	Type	Application Number	Filing Date	Country	Status
30696-727.7821	MODULAR POINT-OF-CARE DEVICES, AND USES THEREOF	Utility: Foreign Divisional	a/2013/012110	10/2/2008	Mexico	Pending
30696-727.791	MODULAR POINT-OF-CARE DEVICES, AND USES THEREOF	Utility: Foreign	584963	10/2/2008	New Zealand	Issued
30696-727.811	MODULAR POINT-OF-CARE DEVICES, AND USES THEREOF	Utility: Foreign	2010117267	10/2/2008	Russian Federation	Pending
30696-727.812	MODULAR POINT-OF-CARE DEVICES, AND USES THEREOF	Utility: Foreign Divisional	2013127796	10/2/2008	Russian Federation	Pending
30696-727.821	MODULAR POINT-OF-CARE DEVICES, AND USES THEREOF	Utility: Foreign	201002319-0	10/2/2008	Singapore	Issued
30696-727.822	MODULAR POINT-OF-CARE DEVICES, AND USES THEREOF	Utility: Foreign Divisional	201300584-8	10/2/2008	Singapore	Pending
30696-727.891	MODULAR POINT-OF-CARE DEVICES, AND USES THEREOF	Utility: Foreign	11104252.2	10/2/2008	Hong Kong	Pending
30696-732.201	INTEGRATED HEALTH DATA CAPTURE AND ANALYSIS SYSTEM	Utility: Non-Provisional	12/906,975	10/18/2010	United States	Allowed
30696-732.611	INTEGRATED HEALTH DATA CAPTURE AND ANALYSIS SYSTEM	Utility: Foreign	EP10825481.4	10/18/2010	European Patent Office	Pending
30696-732.681	INTEGRATED HEALTH DATA CAPTURE AND ANALYSIS SYSTEM	Utility: Foreign	2010308329	10/18/2010	Australia	Pending
30696-732.691	INTEGRATED HEALTH DATA CAPTURE AND ANALYSIS SYSTEM	Utility: Foreign	11 2012 009196-4	10/18/2010	Brazil	Pending
30696-732.701	INTEGRATED HEALTH DATA CAPTURE AND ANALYSIS SYSTEM	Utility: Foreign	2,778,270	10/18/2010	Canada	Pending
30696-732.711	INTEGRATED HEALTH DATA CAPTURE AND ANALYSIS SYSTEM	Utility: Foreign	CN 201080057878.9	10/18/2010	China	Pending
30696-732.731	INTEGRATED HEALTH DATA CAPTURE AND ANALYSIS SYSTEM	Utility: Foreign	219324	10/18/2010	Israel	Published

theranos

Attorney Reference	Title	Type	Application Number	Filing Date	Country	Status
30696-732.741	INTEGRATED HEALTH DATA CAPTURE AND ANALYSIS SYSTEM	Utility: Foreign	4056/DELNP/2012	10/18/2010	India	Pending
30696-732.761	INTEGRATED HEALTH DATA CAPTURE AND ANALYSIS SYSTEM	Utility: Foreign	2012-53283	10/18/2010	Japan	Pending
30696-732.771	INTEGRATED HEALTH DATA CAPTURE AND ANALYSIS SYSTEM	Utility: Foreign	10-2012-7013027	10/18/2010	Republic of Korea	Pending
30696-732.781	INTEGRATED HEALTH DATA CAPTURE AND ANALYSIS SYSTEM	Utility: Foreign	MX/a/2012/004620	10/18/2010	Mexico	Pending
30696-732.791	INTEGRATED HEALTH DATA CAPTURE AND ANALYSIS SYSTEM	Utility: Foreign	599873	10/18/2010	New Zealand	Pending
30696-732.792	INTEGRATED HEALTH DATA CAPTURE AND ANALYSIS SYSTEM	Utility: Divisional	624935	5/13/2014	New Zealand	Pending
30696-732.811	INTEGRATED HEALTH DATA CAPTURE AND ANALYSIS SYSTEM	Utility: Foreign	201202826-2	10/18/2010	Russian Federation	Pending
30696-732.821	INTEGRATED HEALTH DATA CAPTURE AND ANALYSIS SYSTEM	Utility: Foreign	201202826-2	10/18/2010	Singapore	Pending
30696-732.861	INTEGRATED HEALTH DATA CAPTURE AND ANALYSIS SYSTEM	Utility: Foreign	1201001761	10/18/2010	Thailand	Pending
30696-732.891	INTEGRATED HEALTH DATA CAPTURE AND ANALYSIS SYSTEM	Utility: Foreign	13103965	10/18/2010	Hong Kong	Pending
30696-732.911	INTEGRATED HEALTH DATA CAPTURE AND ANALYSIS SYSTEM	Utility: Foreign	PI2012001739	10/18/2010	Malaysia	Pending
30696-733.201	SYSTEMS AND METHODS FOR SAMPLE USE MAXIMIZATION	Utility: Non-Provisional	13/355,458	1/20/2012	United States	Published
30696-733.611	SYSTEMS AND METHODS FOR SAMPLE USE MAXIMIZATION	Utility: Foreign	12 737013.8	1/20/2012	European Patent Office	Published
30696-733.631	SYSTEMS AND METHODS FOR SAMPLE USE MAXIMIZATION	Utility: Foreign	227579	1/20/2012	Israel	Pending
30696-733.681	SYSTEMS AND METHODS FOR SAMPLE USE MAXIMIZATION	Utility: Foreign	2012207090	1/20/2012	Australia	Pending
30696-733.682	SYSTEMS AND METHODS FOR SAMPLE USE MAXIMIZATION	Utility: Divisional	2013205019	1/20/2012	Australia	Pending

theranos

Attorney Reference	Title	Type	Application Number	Filing Date	Country	Status
30696-733.683	SYSTEMS AND METHODS FOR SAMPLE USE MAXIMIZATION	Utility: Divisional	2013205020	1/20/2012	Australia	Pending
30696-733.691	SYSTEMS AND METHODS FOR SAMPLE USE MAXIMIZATION	Utility: Foreign	BR 11 2013 018656-9	1/20/2012	Brazil	Pending
30696-733.701	SYSTEMS AND METHODS FOR SAMPLE USE MAXIMIZATION	Utility: Foreign	2825196	1/20/2012	Canada	Pending
30696-733.711	SYSTEMS AND METHODS FOR SAMPLE USE MAXIMIZATION	Utility: Foreign	2.01E+11	1/20/2012	China	Published
30696-733.731	SYSTEMS AND METHODS FOR SAMPLE USE MAXIMIZATION	Utility: Foreign	227579	1/20/2012	Israel	Published
30696-733.741	SYSTEMS AND METHODS FOR SAMPLE USE MAXIMIZATION	Utility: Foreign	6402/DELNP/2013	1/20/2012	India	Pending
30696-733.761	SYSTEMS AND METHODS FOR SAMPLE USE MAXIMIZATION	Utility: Foreign	2013-550651	1/20/2012	Japan	Published
30696-733.771	SYSTEMS AND METHODS FOR SAMPLE USE MAXIMIZATION	Utility: Foreign	10-2013-7021727	1/20/2012	Republic of Korea	Pending
30696-733.781	SYSTEMS AND METHODS FOR SAMPLE USE MAXIMIZATION	Utility: Foreign	MX/a/2013/008339	1/20/2012	Mexico	Pending
30696-733.791	SYSTEMS AND METHODS FOR SAMPLE USE MAXIMIZATION	Utility: Foreign	613457	1/20/2012	New Zealand	Pending
30696-733.811	SYSTEMS AND METHODS FOR SAMPLE USE MAXIMIZATION	Utility: Foreign	2013137661	1/20/2012	Russian Federation	Pending
30696-733.821	SYSTEMS AND METHODS FOR SAMPLE USE MAXIMIZATION	Utility: Foreign	201305560-3	1/20/2012	Singapore	Pending
30696-733.841	SYSTEMS AND METHODS FOR SAMPLE USE MAXIMIZATION	Utility: Foreign	2013/05478	1/20/2012	South Africa	Pending
30696-733.851	Systems and Methods for Sample Use Maximization	Utility: Foreign	101102769	1/20/2012	Taiwan, Province of China	Pending
30696-733.871	Systems and Methods for Sample Use Maximization	Utility: Foreign	20120100204	1/20/2012	Argentina	Published

theranos

Attorney Reference	Title	Type	Application Number	Filing Date	Country	Status
30696-733.891	SYSTEMS AND METHODS FOR SAMPLE USE MAXIMIZATION	Utility: Foreign	14105512.2	6/11/2014	Hong Kong	Pending
30696-737.201	DRUG MONITORING AND REGULATION SYSTEMS AND METHODS	Utility: Non-Provisional	14/059,173	10/21/2013	United States	Published
30696-737.601	DRUG MONITORING AND REGULATION SYSTEMS AND METHODS	Utility: PCT	PCT/US13/66238	10/22/2013	World Intellectual Property Organization	Published
30696-738.201	METHODS FOR DETECTING AND MEASURING AGGREGATION	Utility: Non-Provisional	13/944,857	7/17/2013	United States	Published
30696-738.601	METHODS FOR DETECTING AND MEASURING AGGREGATION	Utility: PCT	PCT/US13/51165	7/18/2013	World Intellectual Property Organization	Published
30696-740.301	SYSTEMS AND METHODS FOR FLUID HANDLING	Utility: Continuation	13/933,035	7/1/2013	United States	Published
30696-740.501	SYSTEMS AND METHODS FOR MULTI-ANALYSIS	Utility: Non-Provisional	13/244,947	9/26/2011	United States	Issued
30696-740.502	Systems and methods for multi-purpose analysis	Utility: Non-Provisional	13/244,949	9/26/2011	United States	Published
30696-740.503	SYSTEMS AND METHODS FOR DIAGNOSIS OR TREATMENT	Utility: Non-Provisional	13/244,956	9/26/2011	United States	Published
30696-740.504	SYSTEMS AND METHODS FOR FLUID HANDLING	Utility: Non-Provisional	13/244,952	9/26/2011	United States	Issued
30696-740.505	FLUID HANDLING APPARATUS AND CONFIGURATIONS	Utility: Non-Provisional	13/244,950	9/26/2011	United States	Published
30696-740.507	CENTRIFUGE CONFIGURATIONS	Utility: Non-Provisional	13/244,954	9/26/2011	United States	Published
30696-740.601	SYSTEMS AND METHODS FOR MULTI-PURPOSE ANALYSIS	Utility: PCT	PCT/US11/53188	9/25/2011	World Intellectual Property Organization	Published

theranos

Attorney Reference	Title	Type	Application Number	Filing Date	Country	Status
30696-740.602	SYSTEMS AND METHODS FOR MULTI-ANALYSIS	Utility: PCT	PCT/US12/57155	9/25/2012	World Intellectual Property Organization	Published
30696-740.681	SYSTEMS AND METHODS FOR MULTI-ANALYSIS	Utility: Foreign	2012318963	9/25/2012	Australia	Pending
30696-740.682	SYSTEMS AND METHODS FOR MULTI-ANALYSIS	Utility: Divisional	2013205132	9/25/2012	Australia	Pending
30696-740.683	SYSTEMS AND METHODS FOR MULTI-ANALYSIS	Utility: Divisional	2013205139	9/25/2012	Australia	Pending
30696-740.684	SYSTEMS AND METHODS FOR MULTI-ANALYSIS	Utility: Divisional	2013205142	9/25/2012	Australia	Pending
30696-740.851	Systems and Methods for Multi-Analysis	Utility: Foreign	101135220	9/25/2012	Taiwan, Province of China	Pending
30696-740.871	SYSTEMS AND METHODS FOR MULTI-PURPOSE ANALYSIS	Utility: Foreign	20120103532	9/25/2012	Argentina	Pending
30696-741.201	METHODS AND SYSTEMS FOR FACILITATING NETWORK CONNECTIVITY	Utility: Non-Provisional	13/244,836	9/26/2011	United States	Issued
30696-741.301	Methods and Systems for Network Connectivity	Utility: Non-Provisional	13/764,642	2/11/2013	United States	Published
30696-741.601	NETWORK CONNECTIVITY METHODS AND SYSTEMS	Utility: PCT	PCT/US12/57093	9/25/2012	World Intellectual Property Organization	Published
30696-741.681	NETWORK CONNECTIVITY METHODS AND SYSTEMS	Utility: Foreign	2012316309	9/25/2012	Australia	Pending
30696-741.682	NETWORK CONNECTIVITY METHODS AND SYSTEMS	Utility: Divisional	2013204914	9/25/2012	Australia	Pending
30696-741.851	METHODS AND SYSTEMS FOR FACILITATING NETWORK CONNECTIVITY	Utility: Foreign	101135417	9/26/2012	Taiwan, Province of China	Pending

theranos

Attorney Reference	Title	Type	Application Number	Filing Date	Country	Status
30696-743.301	SYSTEMS AND METHODS FOR COLLECTING AND TRANSMITTING ASSAY RESULTS	Utility: Non-Provisional	13/768,748	2/15/2013	United States	Published
30696-743.501	SYSTEMS AND METHODS FOR COLLECTING AND TRANSMITTING ASSAY RESULTS	Utility: Non-Provisional	13/244,946	9/26/2011	United States	Issued
30696-743.601	SYSTEMS AND METHODS FOR COLLECTING AND TRANSMITTING ASSAY RESULTS	Utility: PCT	PCT/US11/53189	9/25/2011	World Intellectual Property Organization	Published
30696-745.201	ASSISTED MEDICAL AND ASSOCIATED LIFESTYLE DECISION MAKING	Utility: Non-Provisional	14/059,195	10/21/2013	United States	Published
30696-745.601	ASSISTED MEDICAL AND ASSOCIATED LIFESTYLE DECISION MAKING	Utility: PCT	PCT/US13/65981	10/21/2013	World Intellectual Property Organization	Published
30696-749.201	INFORMATION MANAGEMENT SYSTEMS AND METHODS USING A BIOLOGICAL SIGNATURE	Utility: Non-Provisional	14/019,946	9/6/2013	United States	Published
30696-749.601	INFORMATION MANAGEMENT SYSTEMS AND METHODS USING A BIOLOGICAL SIGNATURE	Utility: PCT	PCT/US13/58450	9/6/2013	World Intellectual Property Organization	Published
30696-751.201	LOW-VOLUME COAGULATION ASSAY	Utility: Non-Provisional	13/944,863	7/17/2013	United States	Published
30696-751.601	LOW-VOLUME COAGULATION ASSAY	Utility: PCT	PCT/US2013/051162	7/18/2013	World Intellectual Property Organization	Published
713.302	REAL-TIME DETECTION OF INFLUENZA VIRUS	Utility: Non-Provisional	14/155,150	1/14/2014	United States	Pending
720.302	Detection and Quantification of Analytes in Bodily Fluids	Utility: Non-Provisional	14/285,562	5/22/2014	United States	Pending
722.502	Systems and Methods of Sample Processing and Fluid Control in a Fluidic System	Utility: Non-Provisional	14/270,618	5/6/2014	United States	Pending

theranos

Attorney Reference	Title	Type	Application Number	Filing Date	Country	Status
727.892	MODULAR POINT-OF-CARE DEVICES, AND USES THEREOF	Utility: Non-Provisional	14103531.4	4/11/2014	Hong Kong	Published
739.201	METHODS, SYSTEMS, AND DEVICES FOR REAL TIME EXECUTION AND OPTIMIZATION OF CONCURRENT TEST PROTOCOLS ON A SINGLE DEVICE	Utility: Non-Provisional	14/181,486	2/14/2014	United States	Pending
739.601	METHODS, SYSTEMS, AND DEVICES FOR REAL TIME EXECUTION AND OPTIMIZATION OF CONCURRENT TEST PROTOCOLS ON A SINGLE DEVICE	Utility: PCT	PCT/US14/16548	2/14/2014	World Intellectual Property Organization	Pending
740.611	SYSTEMS AND METHODS FOR MULTI-ANALYSIS	Utility: Foreign	12 838242.1	3/20/2014	European Patent Office	Pending
740.691	SYSTEMS AND METHODS FOR MULTI-ANALYSIS	Utility: Foreign	BR11 2014 007073-3	3/25/2014	Brazil	Pending
740.701	SYSTEMS AND METHODS FOR MULTI-ANALYSIS	Utility: Foreign	2,849,104	3/18/2014	Canada	Pending
740.711	SYSTEMS AND METHODS FOR MULTI-ANALYSIS	Utility: Foreign	2.01E+11	5/23/2014	China	Pending
740.731	SYSTEMS AND METHODS FOR MULTI-ANALYSIS	Utility: Foreign	231639	3/20/2014	Israel	Pending
740.741	SYSTEMS AND METHODS FOR MULTI-ANALYSIS	Utility: Foreign	2197/DELNP/2014	3/22/2014	India	Pending
740.761	SYSTEMS AND METHODS FOR MULTI-ANALYSIS	Utility: Foreign		3/24/2014	Japan	Pending
740.771	SYSTEMS AND METHODS FOR MULTI-ANALYSIS	Utility: Foreign	10-2014-7011324	4/25/2014	Republic of Korea	Pending
740.781	SYSTEMS AND METHODS FOR MULTI-ANALYSIS	Utility: Foreign	MX/a/2014/002991	3/13/2014	Mexico	Pending
740.811	SYSTEMS AND METHODS FOR MULTI-ANALYSIS	Utility: Foreign	2014109864	3/14/2014	Russian Federation	Pending
740.821	SYSTEMS AND METHODS FOR MULTI-ANALYSIS	Utility: Foreign	11201400832S	3/20/2014	Singapore	Pending

theranos

Attorney Reference	Title	Type	Application Number	Filing Date	Country	Status
740.841	SYSTEMS AND METHODS FOR MULTI-ANALYSIS	Utility: Foreign	2014/02984	4/24/2014	South Africa	Pending
740.861	SYSTEMS AND METHODS FOR MULTI-ANALYSIS	Utility: Foreign	1401001625	3/25/2014	Thailand	Pending
741.611	NETWORK CONNECTIVITY METHODS AND SYSTEMS	Utility: Foreign	12836129.2	4/25/2014	European Patent Office	Pending
741.711	NETWORK CONNECTIVITY METHODS AND SYSTEMS	Utility: Foreign	2.01E+11	5/26/2014	China	Pending
741.741	NETWORK CONNECTIVITY METHODS AND SYSTEMS	Utility: Foreign	3282/DELNP/2014	4/23/2014	India	Pending
741.761	NETWORK CONNECTIVITY METHODS AND SYSTEMS	Utility: Foreign		3/26/2014	Japan	Pending
741.771	NETWORK CONNECTIVITY METHODS AND SYSTEMS	Utility: Foreign	10-2014-7011290	4/25/2014	Republic of Korea	Pending
D001.101	SAMPLE CONTAINER	Design	29/466,411	9/6/2013	United States	Pending
D001.102	SAMPLE CONTAINER	Design	29/466,412	9/6/2013	United States	Pending
D001.103	SAMPLE CONTAINER	Design	29/466,413	9/6/2013	United States	Pending
D001.104	SAMPLE CONTAINER	Design	29/466,415	9/6/2013	United States	Pending
D002.101	Blood Collection Device	Design	29/466,434	9/8/2013	United States	Pending
D002.102	Blood Collection Device	Design	29/466,435	9/8/2013	United States	Pending
D002.103	Blood Collection Device	Design	29/466,436	9/8/2013	United States	Pending
D002.104	Blood Collection Device	Design	29/466,437	9/8/2013	United States	Pending
D003.101	VENOUS BLOOD COLLECTION DEVICE	Design	29/466,438	9/8/2013	United States	Pending
D003.102	VENOUS BLOOD COLLECTION DEVICE	Design	29/466,439	9/8/2013	United States	Pending
D004.101	Shipping Container	Design	29/466,440	9/8/2013	United States	Pending
D004.102	SHIPPING CONTAINER	Design	29/466,441	9/8/2013	United States	Pending
D004.103	Shipping Container	Design	29/466,442	9/8/2013	United States	Pending
D004.104	Shipping Container	Design	29/466,443	9/8/2013	United States	Pending
D004.105	SHIPPING CONTAINER	Design	29/466,710	9/10/2013	United States	Pending
D004.106	SHIPPING CONTAINER	Design	29/466,739	9/11/2013	United States	Pending

theranos

Attorney Reference	Title	Type	Application Number	Filing Date	Country	Status
D005.101	FINGER WARMER	Design	29/467,883	9/24/2013	United States	Allowed
D006.103	NOVELTY BLOOD COLLECTION DEVICE	Design	29/466,709	9/10/2013	United States	Pending

Trade mark Summary

theranos

Trademark Status Report (by mark)

Trademark	*Country*	*Class*	*App. Date*	*App. No.*	*Reg. Date*	*Reg. No.*	*Status*
ASYMMETRICAL Shape Logo	Brazil	10	10/24/2012	840308965			Abandoned
ASYMMETRICAL Shape Logo	Brazil	44	10/24/2012	840308949			Abandoned
ASYMMETRICAL Shape Logo	Canada	10; 44	10/24/2012	1599491			Abandoned
ASYMMETRICAL Shape Logo	China	10	10/24/2012	11645674			Abandoned
ASYMMETRICAL Shape Logo	China	44	10/24/2012	11645678			Abandoned
ASYMMETRICAL Shape Logo	European Union	10; 42; 44	10/24/2012	011291929	3/22/2013	011291929	Registered - DNR
ASYMMETRICAL Shape Logo	India	10; 44	10/26/2012	2417754			Abandoned
ASYMMETRICAL Shape Logo	Japan	10; 44	10/24/2012	2012086261	11/15/2013	5629827	Registered - DNR
ASYMMETRICAL Shape Logo	Russia	10; 44	10/24/2012	2012736946	12/9/2013	501675	Registered - DNR
ASYMMETRICAL SHAPE Logo	United States	01; 05; 09; 10; 35; 36; 39; 42; 44	4/24/2012	85606355			Abandoned
BASELINE FOR LIFE	United States	09; 42; 44	9/24/2012	85736815			Published
BASELINE OF LIFE	Canada	09; 10; 42; 44	9/27/2013	1645660			Pending
BASELINE OF LIFE	China	09	9/27/2013	13296679			Pending
BASELINE OF LIFE	China	44	9/27/2013	13296678			Pending
BASELINE OF LIFE	European Union	09; 42; 44	9/27/2013	012180121	2/19/2014	012180121	Registered
BASELINE OF LIFE	India	09; 44	9/27/2013	2603414			Pending
BASELINE OF LIFE	Japan	09; 44	9/26/2013	201375216			Pending
BASELINE OF LIFE	Mexico	09	9/26/2013	1416943	1/15/2014	1426576	Registered

theranos

Trademark	Country	Class	App. Date	App. No.	Reg. Date	Reg. No.	Status
BASELINE OF LIFE	Mexico	44	9/26/2013	1416944			Pending
BASELINE OF LIFE	United States	09; 10; 42; 44	3/27/2013	85888176			Published
DASHBOARD FOR LIFE	Brazil	09	10/24/2012	840308990			Published
DASHBOARD FOR LIFE	Canada	09	10/24/2012	1599510			Pending
DASHBOARD FOR LIFE	China	09	10/24/2012	11645671			Published
DASHBOARD FOR LIFE	European Union	09; 42; 44	10/24/2012	011291895	3/22/2013	011291895	Registered
DASHBOARD FOR LIFE	India	09	10/26/2012	2417752			Pending
DASHBOARD FOR LIFE	Japan	09	10/24/2012	2012086263	4/5/2013	5571657	Registered
DASHBOARD FOR LIFE	Norway	09	10/24/2012	201211573	1/30/2013	269204	Registered
DASHBOARD FOR LIFE	Russia	09	10/24/2012	2012736947			Pending
DASHBOARD FOR LIFE	Switzerland	09	10/24/2012	626872012	5/30/2013	644441	Registered
DASHBOARD FOR LIFE	United States	09	4/24/2012	85606333			Allowed
DYNAMIC LAB SERVICES	United States	01; 05; 09; 10; 35; 36; 39; 42; 44	9/24/2012	85736786			Allowed
ELASTIC LAB SERVICES	United States	01; 05; 09; 10; 35; 36; 39; 42; 44	9/24/2012	85736783			Abandoned
GREEN DOT design	Australia	01; 05; 09; 10; 35; 36; 39; 42; 44	12/16/2013	1596941			Pending
GREEN DOT design	Brazil	01	12/13/2013	840738420			Published
GREEN DOT design	Brazil	05	12/13/2013	840738439			Published
GREEN DOT design	Brazil	09	12/13/2013	840738455			Published
GREEN DOT design	Brazil	10	12/13/2013	840738463			Published
GREEN DOT design	Brazil	35	12/13/2013	840738471			Published

theranos

Trademark	Country	Class	App. Date	App. No.	Reg. Date	Reg. No.	Status
GREEN DOT design	Brazil	36	12/13/2013	840738633			Published
GREEN DOT design	Brazil	39	12/13/2013	840738641			Published
GREEN DOT design	Brazil	42	12/13/2013	840738650			Published
GREEN DOT design	Brazil	44	12/13/2013	840738668			Published
GREEN DOT design	Canada	CG; CS; 01; 05; 09; 10; 35; 36; 39; 42; 44	6/28/2013	1633051			Pending
GREEN DOT design	China	01	12/16/2013	13734485			Pending
GREEN DOT design	China	05	12/16/2013	13734484			Pending
GREEN DOT design	China	09	12/16/2013	13734483			Pending
GREEN DOT design	China	10	12/16/2013	13734482			Pending
GREEN DOT design	China	35	12/16/2013	13734481			Pending
GREEN DOT design	China	36	12/16/2013	13734480			Pending
GREEN DOT design	China	39	12/16/2013	13734461			Pending
GREEN DOT design	China	42	12/16/2013	13734479			Pending
GREEN DOT design	China	44	12/16/2013	13734478			Pending
GREEN DOT design	European Union	01; 05; 09; 10; 35; 36; 39; 42; 44	6/14/2013	011902889			Abandoned
GREEN DOT design	European Union	01; 05; 09; 10; 35; 36; 39; 42; 44					Proposed
GREEN DOT design	Hong Kong	01; 05; 09; 10; 35; 36; 39; 42; 44	12/13/2013	302837160			Pending
GREEN DOT design	India	01; 05; 09; 10; 35; 36; 39; 42; 44	12/13/2013	2642621			Pending

theranos

Trademark	*Country*	*Class*	*App. Date*	*App. No.*	*Reg. Date*	*Reg. No.*	*Status*
GREEN DOT design	Israel	01; 05; 09; 10; 35; 36; 39; 42; 44	12/14/2013	261331			Pending
GREEN DOT design	Japan	01; 05; 09; 10; 35; 36; 39; 42; 44	12/16/2013	201398722			Abandoned
GREEN DOT design	Mexico	01	12/13/2013	1441276			Pending
GREEN DOT design	Mexico	05	12/13/2013	1441277			Pending
GREEN DOT design	Mexico	09	12/13/2013	1441278			Pending
GREEN DOT design	Mexico	10	12/13/2013	1441279	3/24/2014	1441667	Registered
GREEN DOT design	Mexico	35	12/13/2013	1441280			Pending
GREEN DOT design	Mexico	36	12/13/2013	1441281			Pending
GREEN DOT design	Mexico	39	12/13/2013	1441282			Pending
GREEN DOT design	Mexico	42	12/13/2013	1441283			Pending
GREEN DOT design	Mexico	44	12/13/2013	1441284			Pending
GREEN DOT design	Norway	01; 05; 09; 10; 35; 36; 39; 42; 44	12/13/2013	201315058			Pending
GREEN DOT design	Russia	01; 05; 09; 10; 35; 36; 39; 42; 44	12/13/2013	2013743598			Pending
GREEN DOT design	Singapore	01; 05; 09; 10; 35; 36; 39; 42; 44	12/13/2013	T1320233G			Pending
GREEN DOT design	South Korea	01; 05; 09; 10; 35; 36; 39; 42; 44	12/16/2013	4520130007566			Pending
GREEN DOT design	Switzerland	01; 05; 09; 10; 35; 36; 39; 42; 44	12/13/2013	650062013			Pending
GREEN DOT design	Taiwan	01; 05; 09; 10; 35; 36; 39; 42; 44	12/13/2013	102070195			Pending

theranos

Trademark	Country	Class	App. Date	App. No.	Reg. Date	Reg. No.	Status
GREEN DOT design	Thailand	01	12/13/2013				Pending
GREEN DOT design	Thailand	05	12/13/2013				Pending
GREEN DOT design	Thailand	09	12/13/2013				Pending
GREEN DOT design	Thailand	10	12/13/2013				Pending
GREEN DOT design	Thailand	35	12/13/2013				Pending
GREEN DOT design	Thailand	36	12/13/2013				Pending
GREEN DOT design	Thailand	39	12/13/2013				Pending
GREEN DOT design	Thailand	42	12/13/2013				Pending
GREEN DOT design	Thailand	44	12/13/2013				Pending
GREEN DOT design	United States	01; 05; 09; 10; 35; 36; 39; 42; 44	6/14/2013	85960711			Pending
HEALTH ASSISTANT	Brazil	09	10/24/2012	840309015			Published
HEALTH ASSISTANT	Canada	09	10/24/2012	1599511			Pending
HEALTH ASSISTANT	China	09	10/24/2012	11645673			Abandoned
HEALTH ASSISTANT	European Union	09; 42; 44	10/24/2012	011291903	3/22/2013	011291903	Registered
HEALTH ASSISTANT	India	09	10/26/2012	2417751			Pending
HEALTH ASSISTANT	Japan	09	10/24/2012	2012086264	4/5/2013	5571658	Registered
HEALTH ASSISTANT	Russia	09	10/24/2012	2012736948			Pending
HEALTH ASSISTANT	South Korea	09	10/24/2012	4020120066098	12/31/2013	401015261	Registered
HEALTH ASSISTANT	Taiwan	09	10/24/2012	101060364	4/1/2013	01572500	Registered
HEALTH ASSISTANT	United States	09	4/24/2012	85606350			Suspended
INDIVIDUALIZED HEALTH	United States	01; 05; 09; 10; 35; 36; 39; 42; 44	9/24/2012	85736797			Abandoned

theranos

Trademark	Country	Class	App. Date	App. No.	Reg. Date	Reg. No.	Status
INDIVIDUALIZED HEALTHCARE	Brazil	09	3/25/2013	840461399			Published
INDIVIDUALIZED HEALTHCARE	Brazil	44	3/25/2013	840461410			Published
INDIVIDUALIZED HEALTHCARE	Canada	01; 05; 09; 10; 35; 36; 39; 42; 44	3/25/2013	1619644			Pending
INDIVIDUALIZED HEALTHCARE	China	09	3/25/2013	12316237			Abandoned
INDIVIDUALIZED HEALTHCARE	China	44	3/25/2013	12316236			Abandoned
INDIVIDUALIZED HEALTHCARE	European Union	09; 10; 44	3/25/2013	011684453			Abandoned
INDIVIDUALIZED HEALTHCARE	India	09; 44	3/25/2013	2502258			Pending
INDIVIDUALIZED HEALTHCARE	Japan	09; 44	3/25/2013	2013021476			Pending
INDIVIDUALIZED HEALTHCARE	Russia	09; 44	3/25/2013	2013709683			Pending
INDIVIDUALIZED HEALTHCARE	Singapore	09; 44	3/25/2013	T1304803F			Pending
INDIVIDUALIZED HEALTHCARE	South Korea	09; 44	3/25/2013	4520130001618			Pending
INDIVIDUALIZED HEALTHCARE	Taiwan	09; 44	3/25/2013	102015705			Pending
INDIVIDUALIZED HEALTHCARE	United States	01; 05; 09; 10; 35; 36; 39; 42; 44	9/24/2012	85736804			Abandoned
INSPIRED BY YOU	United States	44	9/5/2012	85721484			Allowed
KNOW MORE, DO MORE	European Union	09; 35; 36; 44	6/14/2013	011902905			Abandoned
KNOW MORE. DO MORE	Australia	09; 35; 36; 44	12/16/2013	A0039841			Pending - Intl Reg
KNOW MORE. DO MORE	Canada	CG; CS; 09; 35; 36; 44	6/28/2013	1633052			Pending
KNOW MORE. DO MORE	China	09; 35; 36; 44	12/16/2013	A0039841			Pending - Intl Reg
KNOW MORE. DO MORE	India	09; 35; 36; 44	12/16/2013	A0039841			Pending - Intl Reg

theranos

Trademark	Country	Class	App. Date	App. No.	Reg. Date	Reg. No.	Status
KNOW MORE. DO MORE	Israel	09; 35; 36; 44	12/16/2013	A0039841			Pending - Intl Reg
KNOW MORE. DO MORE	Japan	09; 35; 36; 44	12/16/2013	A0039841			Pending - Intl Reg
KNOW MORE. DO MORE	Mexico	09; 35; 36; 44	12/16/2013	A0039841			Pending - Intl Reg
KNOW MORE. DO MORE	Norway	09; 35; 36; 44	12/16/2013	A0039841			Pending - Intl Reg
KNOW MORE. DO MORE	Philippines	09; 35; 36; 44	12/16/2013	A0039841			Pending - Intl Reg
KNOW MORE. DO MORE	Russia	09; 35; 36; 44	12/16/2013	A0039841			Pending - Intl Reg
KNOW MORE. DO MORE	Singapore	09; 35; 36; 44	12/16/2013	A0039841			Pending - Intl Reg
KNOW MORE. DO MORE	South Korea	09; 35; 36; 44	12/16/2013	A0039841			Pending - Intl Reg
KNOW MORE. DO MORE	Switzerland	09; 35; 36; 44	12/16/2013	A0039841			Pending - Intl Reg
KNOW MORE. DO MORE	United States	09; 35; 36; 44	6/25/2013	85969732			Pending
KNOW MORE. DO MORE	WIPO - Madrid Agreement / Protocol	09; 35; 36; 44	12/16/2013	A0039841			Pending - Intl Reg
LAAS	Brazil	09	3/5/2013	840440405			Published
LAAS	Brazil	42	3/5/2013	840440413			Published
LAAS	Brazil	44	3/5/2013	840440286			Published
LAAS	Canada	09; 42; 44	3/5/2013	1616792			Pending
LAAS	China	09	3/5/2013	12212805			Published
LAAS	China	42	3/5/2013	12212804			Published
LAAS	China	44	3/5/2013	12212803			Pending
LAAS	European Union	09; 42; 44	3/5/2013	011626009			Opposed

theranos

Trademark	Country	Class	App. Date	App. No.	Reg. Date	Reg. No.	Status
LAAS	India	09; 42; 44	3/5/2013	2489867			Pending
LAAS	Japan	09; 42; 44	3/5/2013	201315547			Pending
LAAS	Russia	09; 42; 44	3/5/2013	2013707072			Pending
LAAS	South Korea	42	3/5/2013	4520130001194			Pending
LAAS	Taiwan	09; 42; 44	3/5/2013	102011389			Pending
LAAS	United States	09; 42; 44	9/5/2012	85721482			Allowed
LBM	United States	09; 35; 36; 42; 44	4/24/2012	85606339			Pending
LIFE QUANTIFIED	United States	01; 05; 09; 10; 35; 36; 39; 42; 44	9/24/2012	85736806			Published
NANOTAINER	Australia	05; 10; 39; 44	10/24/2012	1521718	6/4/2014	1521718	Registered
NANOTAINER	Brazil	05	10/24/2012	840309040			Published
NANOTAINER	Brazil	10	10/24/2012	840309031			Published
NANOTAINER	Brazil	39	10/24/2012	840309023			Published
NANOTAINER	Brazil	44	10/24/2012	840308981			Published
NANOTAINER	Canada	05; 10; 39; 44	10/24/2012	1599489			Pending
NANOTAINER	China	01	10/24/2012	11645679			Published
NANOTAINER	China	05	10/24/2012	11645675			Published
NANOTAINER	China	10	10/24/2012	11645670			Published
NANOTAINER	China	39	10/24/2012	11645677			Published
NANOTAINER	China	42	10/24/2012	11645676			Published
NANOTAINER	China	44	10/24/2012	11645672			Published
NANOTAINER	European Union	05; 10; 39; 44	10/24/2012	011291911	3/22/2013	011291911	Registered

theranos

Trademark	Country	Class	App. Date	App. No.	Reg. Date	Reg. No.	Status
NANOTAINER	Hong Kong	05; 10; 39; 44	10/24/2012	302413511			Published
NANOTAINER	India	05; 10; 39; 44	10/26/2012	2417753			Pending
NANOTAINER	Israel	05; 10; 39; 44	10/24/2012	250344			Published
NANOTAINER	Japan	01; 05; 10; 39; 42; 44	10/24/2012	2012086262			Pending
NANOTAINER	Mexico	05	10/24/2012	1320631	2/18/2013	1349090	Registered
NANOTAINER	Mexico	10	10/24/2012	1320630	3/19/2013	1355080	Registered
NANOTAINER	Mexico	35	7/16/2013	1393186			Pending
NANOTAINER	Mexico	39	10/24/2012	1320629			Pending
NANOTAINER	Mexico	44	10/24/2012	1320627	12/5/2013	1417737	Registered
NANOTAINER	Norway	05; 10; 39; 44	10/24/2012	201211572	1/30/2013	269203	Registered
NANOTAINER	Russia	01; 05; 10; 39; 42	10/24/2012	2012736943			Published
NANOTAINER	Singapore	05; 10; 39; 44	10/24/2012	T1215864D			Pending
NANOTAINER	South Korea	01; 05; 10	10/24/2012	4520120005455			Pending
NANOTAINER	South Korea	39; 42; 44	10/29/2013	4120130041212			Pending
NANOTAINER	Switzerland	05; 10; 39; 44	10/24/2012	626982012	7/9/2013	645943	Registered
NANOTAINER	Taiwan	01; 05; 10; 39; 42; 44	10/24/2012	101060363			Pending
NANOTAINER	United States	01; 05; 09; 10; 35; 36; 39; 42; 44	4/24/2012	85606345			Opposed
QUANTIFIED LIFE	Brazil	09	3/25/2013	840461429			Published
QUANTIFIED LIFE	Brazil	44	3/25/2013	840461445			Published

theranos

Trademark	*Country*	*Class*	*App. Date*	*App. No.*	*Reg. Date*	*Reg. No.*	*Status*
QUANTIFIED LIFE	Canada	01; 05; 09; 10; 35; 36; 39; 42; 44	3/25/2013	1619643			Pending
QUANTIFIED LIFE	China	09	3/25/2013	12316235			Published
QUANTIFIED LIFE	China	44	3/25/2013	12316234			Published
QUANTIFIED LIFE	European Union	09; 10; 44	3/25/2013	011684461	9/19/2013	011684461	Registered
QUANTIFIED LIFE	India	09; 44	3/25/2013	2502259			Pending
QUANTIFIED LIFE	Japan	09; 44	3/25/2013	2013021478			Pending
QUANTIFIED LIFE	Russia	09; 44	3/25/2013	2013709684			Pending
QUANTIFIED LIFE	Singapore	09; 44	3/25/2013	T1304806J			Pending
QUANTIFIED LIFE	South Korea	09; 44	3/25/2013	4520130001619			Pending
QUANTIFIED LIFE	Taiwan	09; 44	3/25/2013	102015707			Pending
QUANTIFIED LIFE	United States	01; 05; 09; 10; 35; 36; 39; 42; 44	9/24/2012	85736811			Pending
QUANTIFY ME	United States	01; 05; 09; 10; 35; 36; 39; 42; 44	9/24/2012	85736808			Published
REDEFINING HEALTHCARE	Brazil	09	3/25/2013	840461364			Published
REDEFINING HEALTHCARE	Brazil	10	3/25/2013	840461380			Published
REDEFINING HEALTHCARE	Brazil	44	3/25/2013	840461356			Published
REDEFINING HEALTHCARE	Canada	01; 05; 09; 10; 35; 36; 39; 42; 44	3/25/2013	1619642			Pending
REDEFINING HEALTHCARE	China	09	3/25/2013	12316240			Abandoned
REDEFINING HEALTHCARE	China	10	3/25/2013	12316239			Abandoned
REDEFINING HEALTHCARE	China	44	3/25/2013	12316238			Abandoned
REDEFINING HEALTHCARE	European Union	09; 10; 44	3/25/2013	011684438			Abandoned

theranos

Trademark	Country	Class	App. Date	App. No.	Reg. Date	Reg. No.	Status
REDEFINING HEALTHCARE	India	09; 10; 44	3/25/2013	2502257			Pending
REDEFINING HEALTHCARE	Japan	09; 10; 44	3/25/2013	201321475			Pending
REDEFINING HEALTHCARE	Russia	09; 10; 44	3/25/2013	2013709682			Pending
REDEFINING HEALTHCARE	Singapore	09; 10; 44	3/25/2013	T1304801Z			Pending
REDEFINING HEALTHCARE	South Korea	09; 10; 44	3/25/2013	4520130001617			Published
REDEFINING HEALTHCARE	Taiwan	09; 10; 44	3/25/2013	102015713			Pending
REDEFINING HEALTHCARE	United States	01; 05; 09; 10; 35; 36; 39; 42; 44	9/24/2012	85736791			Published
THERABOX	Australia	10; 11; 20; 35; 39; 44	7/24/2013	A0037039		IR 1199662	Pending - Intl Reg
THERABOX	Brazil	10	7/29/2013	840590920			Published
THERABOX	Brazil	11	7/29/2013	840590903			Published
THERABOX	Brazil	39	7/29/2013	840590911			Published
THERABOX	Canada	CG; CS; 10; 11; 20; 35; 39; 44	7/23/2013	1636406			Pending
THERABOX	China	10; 11; 20; 35; 39; 44	7/24/2013	A0037039		IR 1199662	Pending - Intl Reg
THERABOX	European Union	10; 11; 20; 35; 39; 44	7/24/2013	A0037039		IR 1199662	Pending - Intl Reg
THERABOX	India	10; 11; 20; 35; 39; 44	7/24/2013	A0037039		IR 1199662	Pending - Intl Reg
THERABOX	Israel	10; 11; 20; 35; 39; 44	7/24/2013	A0037039		IR 1199662	Pending - Intl Reg
THERABOX	Japan	10; 11; 20; 35; 39; 44	7/24/2013	A0037039		IR 1199662	Pending - Intl Reg
THERABOX	Mexico	10; 11; 20; 35; 39; 44	7/24/2013	A0037039		IR 1199662	Pending - Intl Reg
THERABOX	Norway	10; 11; 20; 35; 39; 44	7/24/2013	A0037039		IR 1199662	Pending - Intl Reg

theranos

Trademark	Country	Class	App. Date	App. No.	Reg. Date	Reg. No.	Status
THERABOX	Philippines	10; 11; 20; 35; 39; 44	7/24/2013	A0037039		IR 1199662	Pending - Intl Reg
THERABOX	Russia	10; 11; 20; 35; 39; 44	7/24/2013	A0037039		IR 1199662	Pending - Intl Reg
THERABOX	Singapore	10; 11; 20; 35; 39; 44	7/24/2013	A0037039		IR 1199662	Pending - Intl Reg
THERABOX	South Korea	10; 11; 20; 35; 39; 44	7/24/2013	A0037039		IR 1199662	Pending - Intl Reg
THERABOX	Switzerland	10; 11; 20; 35; 39; 44	7/24/2013	A0037039		IR 1199662	Pending - Intl Reg
THERABOX	United States	10; 11; 20; 35; 36; 39; 44	1/25/2013	85832697			Published
THERABOX	WIPO - Madrid Agreement / Protocol	10; 11; 20; 35; 39; 44	7/24/2013	A0037039	7/24/2013	IR 1199662	Registered - Intl Reg
THERACARE	United States	01; 05; 09; 10; 35; 36; 39; 42; 44	9/24/2012	85736813			Published
THERANALYSIS	Brazil	09	3/5/2013	840440421			Published
THERANALYSIS	Brazil	42	3/5/2013	840440324			Published
THERANALYSIS	Brazil	44	3/5/2013	840440359			Published
THERANALYSIS	Canada	09; 42; 44	3/5/2013	1616791			Pending
THERANALYSIS	China	09	3/5/2013	12212808			Published
THERANALYSIS	China	42	3/5/2013	12212807			Published
THERANALYSIS	China	44	3/5/2013	12212806			Pending
THERANALYSIS	European Union	09; 42; 44	3/5/2013	011625977	9/11/2013	011625977	Registered
THERANALYSIS	India	09; 42; 44	3/5/2013	2489866			Pending
THERANALYSIS	Japan	09; 42; 44	3/5/2013	201315546			Pending
THERANALYSIS	Russia	09; 42; 44	3/5/2013	2013707077			Pending

theranos

Trademark	Country	Class	App. Date	App. No.	Reg. Date	Reg. No.	Status
THERANALYSIS	South Korea	09; 42; 44	3/5/2013	4520130001193			Published
THERANALYSIS	Taiwan	09; 42; 44	3/5/2013	102011388			Pending
THERANALYSIS	United States	09; 42; 44	9/5/2012	85721480			Allowed
THERANOPSIS	United States	09; 42; 44	9/5/2012	85721481			Allowed
THERANOS	Australia	01; 05; 09; 10; 35; 36; 39; 42; 44	1/9/2013	1534749			Pending
THERANOS	Brazil	01	2/14/2013	840419473			Published
THERANOS	Brazil	05	2/14/2013	840419457			Published
THERANOS	Brazil	09	2/14/2013	840419430			Published
THERANOS	Brazil	10	2/14/2013	840419422			Published
THERANOS	Brazil	35	2/14/2013	840419520			Published
THERANOS	Brazil	36	2/14/2013	840419503			Published
THERANOS	Brazil	39	2/14/2013	840419490			Published
THERANOS	Brazil	42	2/14/2013	840419481			Published
THERANOS	Brazil	44	2/14/2013	840419546			Published
THERANOS	Canada	01; 09; 35; 36; 39	3/5/2013	1616912			Pending
THERANOS	Canada	CG; CS	12/19/2007	1376743	1/18/2011	TMA787792	Registered
THERANOS	China	01	3/5/2013	12212802			Published
THERANOS	China	01	12/12/2007	6433097	3/28/2010	6433097	Registered
THERANOS	China	05	12/12/2007	6433096			Abandoned
THERANOS	China	05	3/5/2013	12212801			Pending
THERANOS	China	09	3/5/2013	12212800			Published
THERANOS	China	10	11/12/2009	7828549			Abandoned

theranos

Trademark	Country	Class	App. Date	App. No.	Reg. Date	Reg. No.	Status
THERANOS	China	10	3/5/2013	12212799			Published
THERANOS	China	10	12/12/2007	6433095	12/28/2010	6433095	Registered
THERANOS	China	35	3/5/2013	12212798			Published
THERANOS	China	36	3/5/2013	12212797			Published
THERANOS	China	39	3/5/2013	12212796			Published
THERANOS	China	42	3/5/2013	12212795			Published
THERANOS	China	44	3/5/2013	12212794			Pending
THERANOS	China	44	12/12/2007	6433094	4/14/2010	6433094	Registered
THERANOS	European Union	01; 05; 09; 10; 35; 36; 39; 42; 44	3/5/2013	011625852	9/2/2013	011625852	Registered
THERANOS	European Union	05; 10; 42; 44	4/18/2006	005025697	6/10/2009	005025697	Registered
THERANOS	Hong Kong	01; 05; 09; 10; 35; 36; 39; 42; 44	1/24/2013	302505816			Published
THERANOS	India	01; 05; 09; 10; 35; 36; 39; 42; 44	3/5/2013	2489868			Pending
THERANOS	India	10	12/14/2009	1895665	10/11/2013	1895665	Registered
THERANOS	Israel	01; 05; 09; 10; 35; 36; 39; 42; 44	3/5/2013	253965			Pending
THERANOS	Israel	05	4/20/2006	189372	4/6/2008	189372	Registered
THERANOS	Israel	10	4/20/2006	189376	9/4/2007	189376	Registered
THERANOS	Israel	44	4/20/2006	189377	9/4/2007	189377	Registered
THERANOS	Japan	01; 05; 09; 10; 35; 36; 39; 42; 44	3/5/2013	201315559			Pending
THERANOS	Japan	01; 10; 44	4/18/2006	2006035797	12/7/2007	5096552	Registered

theranos

Trademark	Country	Class	App. Date	App. No.	Reg. Date	Reg. No.	Status
THERANOS	Mexico	01	3/5/2013	1354575			Pending
THERANOS	Mexico	05	12/19/2007	904675			Abandoned
THERANOS	Mexico	05	3/5/2013	1354576			Pending
THERANOS	Mexico	09	3/5/2013	1354577	6/28/2013	1380266	Registered
THERANOS	Mexico	10	12/19/2007	904676			Abandoned
THERANOS	Mexico	10	3/5/2013	1354578			Pending
THERANOS	Mexico	35	3/5/2013	1354580			Pending
THERANOS	Mexico	36	3/5/2013	1354581	7/4/2013	1380902	Registered
THERANOS	Mexico	39	3/5/2013	1354582			Pending
THERANOS	Mexico	42	3/5/2013	1354583	3/19/2014	1440025	Registered
THERANOS	Mexico	44	3/5/2013	1354584			Pending
THERANOS	Mexico	44	12/19/2007	904677	2/29/2008	1028541	Registered
THERANOS	Norway	01; 05; 09; 10; 35; 36; 39; 42; 44	1/24/2013	201301192	4/26/2013	270466	Registered
THERANOS	Russia	01; 05; 09; 10; 35; 36; 39; 42; 44	3/4/2013	2013706881			Pending
THERANOS	Singapore	01; 05; 09; 10; 35; 36; 39; 42; 44	3/5/2013	T1303613E			Pending
THERANOS	Singapore	01; 05; 10; 44	10/24/2007	T0720848E	2/20/2008	T0720848E	Registered
THERANOS	South Korea	01; 05; 09; 10; 35; 36; 39; 42; 44	1/22/2013	4520130000366			Pending
THERANOS	Switzerland	01; 05; 09; 10; 35; 36; 39; 42; 44	3/5/2013	527782013			Pending
THERANOS	Switzerland	05; 10; 44	4/19/2006	535342006	6/6/2006	546665	Registered

theranos

Trademark	Country	Class	App. Date	App. No.	Reg. Date	Reg. No.	Status
THERANOS	Taiwan	01; 05; 09; 10; 35; 36; 39; 42; 44	3/5/2013	102011390			Pending
THERANOS	Taiwan	01; 05; 10; 44	10/25/2007	096050284	8/1/2009	01373326	Registered
THERANOS	Thailand	09	3/5/2013	884142			Pending
THERANOS	Thailand	10	11/27/2009	751413	4/18/2012	347612	Registered
THERANOS	United States	01; 05; 09; 10; 35; 36; 39; 41; 42; 44	9/5/2012	85721486			Allowed
THERANOS	United States	01; 05; 09; 10; 39; 42; 44	8/17/2005	78694877	6/1/2010	3797610	Registered
THERANOS (and DOT design)	Australia	01; 05; 09; 10; 35; 36; 39; 42; 44	12/16/2013	A0039840			Pending - Intl Reg
THERANOS (and DOT design)	Canada	CG; CS; 01; 05; 09; 10; 35; 36; 39; 42; 44	6/28/2013	1633053			Pending
THERANOS (and DOT design)	China	01; 05; 09; 10; 35; 36; 39; 42; 44	12/16/2013	A0039840			Pending - Intl Reg
THERANOS (and DOT design)	European Union	01; 05; 09; 10; 35; 36; 39; 42; 44	6/14/2013	011902822	12/27/2013	011902822	Registered
THERANOS (and DOT design)	India	01; 05; 09; 10; 35; 36; 39; 42; 44	12/16/2013	A0039840			Pending - Intl Reg
THERANOS (and DOT design)	Israel	01; 05; 09; 10; 35; 36; 39; 42; 44	12/16/2013	A0039840			Pending - Intl Reg
THERANOS (and DOT design)	Japan	01; 05; 09; 10; 35; 36; 39; 42; 44	12/16/2013	A0039840			Pending - Intl Reg

theranos

Trademark	Country	Class	App. Date	App. No.	Reg. Date	Reg. No.	Status
THERANOS (and DOT design)	Mexico	01; 05; 09; 10; 35; 36; 39; 42; 44	12/16/2013	A0039840			Pending - Intl Reg
THERANOS (and DOT design)	Norway	01; 05; 09; 10; 35; 36; 39; 42; 44	12/16/2013	A0039840			Pending - Intl Reg
THERANOS (and DOT design)	Philippines	01; 05; 09; 10; 35; 36; 39; 42; 44	12/16/2013	A0039840			Pending - Intl Reg
THERANOS (and DOT design)	Russia	01; 05; 09; 10; 35; 36; 39; 42; 44	12/16/2013	A0039840			Pending - Intl Reg
THERANOS (and DOT design)	Singapore	01; 05; 09; 10; 35; 36; 39; 42; 44	12/16/2013	A0039840			Pending - Intl Reg
THERANOS (and DOT design)	South Korea	01; 05; 09; 10; 35; 36; 39; 42; 44	12/16/2013	A0039840			Pending - Intl Reg
THERANOS (and DOT design)	Switzerland	01; 05; 09; 10; 35; 36; 39; 42; 44	12/16/2013	A0039840			Pending - Intl Reg
THERANOS (and DOT design)	United States	01; 05; 09; 10; 35; 36; 39; 42; 44	6/14/2013	85960709			Pending
THERANOS (and DOT design)	WIPO - Madrid Agreement / Protocol	01; 05; 09; 10; 35; 36; 39; 42; 44	12/16/2013	A0039840			Pending - Intl Reg
THERANOS (in Chinese Characters)	China	01	1/4/2008	6492513	3/28/2010	6492513	Registered
THERANOS (in Chinese Characters)	China	05	1/4/2008	6492512	3/28/2010	6492512	Registered
THERANOS (in Chinese Characters)	China	10	1/4/2008	6492511	3/14/2010	6492511	Registered
THERANOS (in Chinese Characters)	China	44	1/4/2008	6492510	4/14/2010	6492510	Registered
THERANOS (in Katakana Characters)	Japan	01; 05; 10; 44	1/7/2008	2008000333	2/27/2009	5209319	Registered
THERANOS ADVANTAGE	United States	01; 05; 09; 10; 35; 36; 39; 42; 44	9/5/2012	85721471			Abandoned

theranos

Trademark	Country	Class	App. Date	App. No.	Reg. Date	Reg. No.	Status
THERANOS BASELINE	United States	01; 05; 09; 10; 35; 36; 39; 42; 44	9/5/2012	85721469			Allowed
THERANOS DOCTOR	United States	01; 05; 09; 10; 35; 36; 39; 42; 44	9/5/2012	85721474			Abandoned
THERANOS LAB	United States	01; 05; 09; 10; 35; 36; 39; 42; 44	9/5/2012	85721477			Allowed
THERANOS Logo	Australia	01; 05; 09; 10; 35; 36; 39; 42; 44	12/14/2013	A0039818			Pending - Intl Reg
THERANOS Logo	Brazil	01	12/13/2013	840738307			Published
THERANOS Logo	Brazil	05	12/13/2013	840738285			Published
THERANOS Logo	Brazil	09	12/13/2013	840738323			Published
THERANOS Logo	Brazil	10	12/13/2013	840738340			Published
THERANOS Logo	Brazil	35	12/13/2013	840738366			Published
THERANOS Logo	Brazil	36	12/13/2013	840738374			Published
THERANOS Logo	Brazil	39	12/13/2013	840738390			Published
THERANOS Logo	Brazil	42	12/13/2013	840738404			Published
THERANOS Logo	Brazil	44	12/13/2013	840738412			Published
THERANOS Logo	Canada	CG; CS; 01; 05; 09; 10; 35; 36; 39; 42; 44	6/28/2013	1633054			Pending
THERANOS Logo	China	01; 05; 09; 10; 35; 36; 39; 42; 44	12/14/2013	A0039818			Pending - Intl Reg
THERANOS Logo	European Union	01; 05; 09; 10; 35; 36; 39; 42; 44	6/14/2013	011902798	12/27/2013	011902798	Registered

theranos

Trademark	Country	Class	App. Date	App. No.	Reg. Date	Reg. No.	Status
THERANOS Logo	Hong Kong	01; 05; 09; 10; 35; 36; 39; 42; 44	12/13/2013	302837043			Published
THERANOS Logo	India	01; 05; 09; 10; 35; 36; 39; 42; 44	12/14/2013	A0039818			Pending - Intl Reg
THERANOS Logo	Israel	01; 05; 09; 10; 35; 36; 39; 42; 44	12/14/2013	A0039818			Pending - Intl Reg
THERANOS Logo	Japan	01; 05; 09; 10; 35; 36; 39; 42; 44	12/14/2013	A0039818			Pending - Intl Reg
THERANOS Logo	Mexico	01; 05; 09; 10; 35; 36; 39; 42; 44	12/14/2013	A0039818			Pending - Intl Reg
THERANOS Logo	Norway	01; 05; 09; 10; 35; 36; 39; 42; 44	12/14/2013	A0039818			Pending - Intl Reg
THERANOS Logo	Philippines	01; 05; 09; 10; 35; 36; 39; 42; 44	12/14/2013	A0039818			Pending - Intl Reg
THERANOS Logo	Russia	01; 05; 09; 10; 35; 36; 39; 42; 44	12/14/2013	A0039818			Pending - Intl Reg
THERANOS Logo	Singapore	01; 05; 09; 10; 35; 36; 39; 42; 44	12/14/2013	A0039818			Pending - Intl Reg
THERANOS Logo	South Korea	01; 05; 09; 10; 35; 36; 39; 42; 44	12/14/2013	A0039818			Pending - Intl Reg
THERANOS Logo	Switzerland	01; 05; 09; 10; 35; 36; 39; 42; 44	12/14/2013	A0039818			Pending - Intl Reg
THERANOS Logo	Taiwan	01; 05; 09; 10; 35; 36; 39; 42; 44	12/13/2013	102070192			Pending
THERANOS Logo	Thailand	01	12/13/2013				Pending
THERANOS Logo	Thailand	05	12/13/2013				Pending

theranos

Trademark	Country	Class	App. Date	App. No.	Reg. Date	Reg. No.	Status
THERANOS Logo	Thailand	09	12/13/2013				Pending
THERANOS Logo	Thailand	10	12/13/2013				Pending
THERANOS Logo	Thailand	35	12/13/2013				Pending
THERANOS Logo	Thailand	36	12/13/2013				Pending
THERANOS Logo	Thailand	39	12/13/2013				Pending
THERANOS Logo	Thailand	42	12/13/2013				Pending
THERANOS Logo	Thailand	44	12/13/2013				Pending
THERANOS Logo	United States	01; 05; 09; 10; 35; 36; 39; 42; 44	6/14/2013	85960653			Pending
THERANOS Logo	WIPO - Madrid Agreement / Protocol	01; 05; 09; 10; 35; 36; 39; 42; 44	12/14/2013	A0039818			Pending - Intl Reg
THERANOS RX	United States	01; 05; 09; 10; 35; 36; 39; 42; 44	6/15/2012	85653736			Allowed
THERANOS TRICORDER	United States	05; 09; 10; 35; 42; 44	9/24/2012	85737220			Published